Nanion Technologies

News and Press

20.06.2017 | Nanion to focus on its own new product portfolio - Axion Biosystems to sell direct in Europe

MUNICH, GERMANY - June, 20th, 2017: Nanion to focus on its own new product portfolio - Axion Biosystems to sell direct in Europe

Axion BioSystems and Nanion Technologies have enjoyed a very productive relationship over the past three years, with Nanion acting as sole distributor of Axion products in Europe. Nanion has effectively penetrated the high-throughput microelectrode array (MEA) market in Europe, while rapidly growing their existing business. Since both companies are undergoing rapid growth, it has been mutually decided that the best approach for both companies is to focus on commercializing their respective product lines.

"We have been pleased with the energy and enthusiasm Nanion invested in Axion's products", says Tom O'Brien, Axion's President and CEO. "It is through Nanion's efforts that we have been able to build a sizable install base of Maestro multiwell MEA systems in Europe. In order to continue this growth trajectory, Axion will establish a larger, dedicated team in Europe focused on sales and applications support."

Nanion has recently moved into a new, larger space anticipating ongoing growth. According to Niels Fertig, Nanion's CEO, "we are facing increasing demand for our existing products. Furthermore, we continue to create innovative new products that address needs in life science research. We feel it is once again time for us to focus on products developed by the Nanion team."

Effective July 1, 2017 Axion products will be sold through Axion BioSystems International. Nanion and Axion will continue to work together through December 31, 2017 to ensure a smooth transition for existing Axion customers, and those currently working with Nanion to acquire Axion products in 2017.

 

May 2017 | New headquarters in Munich

New headquarters in Munich

MUNICH, GERMANY - May, 2017 - Nanion has moved

NewSite

Nanion's Munich headquarters recently moved to new and larger facilities close to the city center.

Niels Fertig, CEO says:
"We found the ideal space within the former laboratories of Daiichi Sankyo Germany and we are very pleased with the new site - a modern building which meets our requirements in terms of technical infrastructure and laboratory facilities. Apart from having a great environment for R&D, production and innovation, these rooms will also serve our clients and collaboration partners for in house training, instrument demonstrations and user meetings."

New address:
Nanion Technologies GmbH
Ganghoferstraße 70 a,
80339 Munich
Germany
phone: +49 89 2190 950-0 

02.02.2017 | Nanion Technologies Launches SURFE2R 96SE Instrument

Nanion Technologies Launches SURFE2R 96SE Instrument

MUNICH, GERMANY - February 2, 2017 - Nanion Technologies is pleased to announce the launch of the new SURFE2R 96SE Instrument for high throughput measurements of electrogenic membrane transporters and pumps.

The SURFE2R 96SE is the first instrument on the market featuring the solid supported membrane (SSM) technology for the robust and simple screening of membrane transporters and pumps in a high throughput manner. With this, the SURFE2R 96SE opens new perspectives in membrane protein screening and investigations for the pharmaceutical industry, offering a label- and radioactivity-free analysis for these difficult targets. Many of these particular proteins are involved in pathological conditions and diseases, or are involved in the transport of pharmacological agents and are of high interest for drug development, but have been difficult to screen so far. The plate-based SURFE2R 96SE addresses the requirement of the pharmaceutical industry, as its technology enables screening of these targets in a simple, cost-efficient and reliable way. Furthermore, the SURFE2R 96SE contains all necessary features for a meaningful HTS screening tool, such as fully-automated sensor preparation and assay-execution, a user-friendly interface, as well as a powerful analysis software. Additionally, Nanion Technologies supports its customers with ready-to use protocols for various experimental procedures.

Read the full press release here.

Download the Product flyer here

 

02.01.2017 |New Genedata Screener® APC Functionality and Integration with Nanion SyncroPatch 384PE

New Genedata Screener® APC Functionality and Integration with Nanion SyncroPatch 384PE at SLAS2017

MUNICH, GERMANY - February 1, 2017 - Genedata, a leading provider of advanced software solutions for drug discovery and life science research, today announced new automated patch clamp (APC) functionality in Genedata Screener for Ion Channel Screening and a Genedata Ready-to-Run integration with Nanion SyncroPatch 384PE. The package provides seamless data capture and innovative analysis of Nanion's multi-sweep, multi-dose current traces as well as interactive access to the raw traces for visualization and analysis optimization. The Genedata Screener/Nanion SyncroPatch 384PE integration will be demonstrated along with the new functionality at an SLAS2017 tutorial session, one of the Genedata Screener events at SLAS2017. Genedata will present at Booth #541; Nanion Technologies will present at Booth #1311 (Walter E. Washington Convention Center, Washington, DC Feb. 4-8).

Read the full press release here.

 

 

27.07.2016 | Icagen Inc.: Entering agreement with Nanion

Icagen Acquires Nanion's SyncroPatch384 High-Throughput Electrophysiology Platform

Entering agreement with Nanion to develop and commercialize innovative ion channel drug discovery solutions - assays for two gene families established

DURHAM, N.C., LIVINGSTON, N.J. and MUNICH, July 27, 2016 /PRNewswire/ -- Icagen, Inc. and Nanion announced today that Icagen has purchased a SyncroPatch384 high-throughput electrophysiology instrument and entered into an agreement to work together to develop ion channel assays for this platform.   The instrument was delivered to Icagen in May 2016 and the company has established assays for two different gene families on the platform to date. Assay panels across specific gene families as well as development of diversity panels such as those used in safety screening across the industry will continually be added.

Douglas Krafte, Ph.D., Chief Scientific Officer, Icagen Inc. stated, "We evaluated the available options in this technology space and are excited to have acquired the Nanion platform and to be working with this company.   We feel that the SyncroPatch384 is the ideal mechanism to leverage Icagen's decades of ion channel drug discovery experience and extensive inventory of cell lines for our customers and clients. In addition, we value the relationship with Nanion and the very high quality of engagement and depth of expertise of their people." 

Rodolfo Haedo, Vice President, Nanion Technologies Inc. added, "Icagen is established in the industry as leaders in ion channel HTS and R&D and have been developing assays of the highest caliber and excellence for many years. As a company that is owned and run by scientists, we believe the synergy between our teams will help further advance the field and establish new paradigms for ion channel discovery and target identification. Merging Icagen's extensive knowledge of ion channel physiology with Nanion's cutting edge technology paves a clear-cut path full of extraordinary possibilities."

Krafte concluded, "We envision this relationship will help us to expedite development of new assays on the platform in response to customer demand including some of the challenging drug discovery targets that our clients often present to us. We anticipate that our relationship with Nanion and development of experience with the platform will further our goal of becoming the first choice in the industry for drug discovery solutions in the ion channel space."

Read full press release here.

See Icagens validation data on different Sodium channels on the SyncroPatch 384PE here.

Find out more about Icagen here.

 

28.06.2016 | Nanion Technologies Opens New Site in Copenhagen

Munich, Germany, June 28, 2016; Nanion Technologies is pleased to announce the opening of a new site in Copenhagen, Denmark. The site contains a fully equipped laboratory and state-of-the-art ion channel high throughput screening platforms, including the SyncroPatch 384/768PE. The new facility within Copenhagen University opens its doors for scientific collaborations, assay development support and product demonstrations.
Nanion is one of the leading providers of high-throughput automated patch clamp systems for industrial screening and academic research. With the inauguration of the facilities at Copenhagen University, and the recent recruitment of Søren Friis, Nanion is optimally positioned to offer excellent customer support to the constantly increasing customer base of the ion channel HTS-platform, the SyncroPatch 384/768PE. In addition, at the new site, Nanion will actively engage in scientific collaborations with researchers in pharma and academia.
Global Sales Director Frank Henrichsen says:
"With the rapidly growing customer base, and thereby increased demand for assay and technical support, we're very happy to have Søren Friis on the team. His solid knowledge of ion channel applications and assay development combined with his dedication to customer support makes him an excellent fit for Nanion. The new facilities at Copenhagen University, and researchers in the area, such as Dr. Kirstine Callø and Dr. Dan Klærke, Faculty of Health and Medical Sciences, UCPH (Frederiksberg Campus) hold great promise for unique scientific collaborations and exciting projects between Nanion and researchers in the pharmaceutical industry and academia."

Søren Friis, Senior Scientist continues:
"I am happy to join the Nanion team, and for the unique opportunity to build a lab in the midst of a flourishing academic community! There has always been a mutual appeal between Nanion and the scientific community, primarily because of the broad range of experimental possibilities offered by Nanion's products. With the new site in Copenhagen, scientists can apply to use the instruments for their specific projects, and for everyone interested in live demonstrations, the SyncroPatch 384/768PE is ready for action."

The inauguration during the 10th FENS Forum of Neuroscience I Copenhagen, will take place on July 4th, 2016 at the premises at IKVH, 100 Dyrlægevej, Frederiksberg, where Nanion will hold an opening ceremony.

About Nanion Technologies:
Nanion Technologies is a one-stop-shop for ion channel drug discovery and screening technologies as well as sophisticated research instrumentation. Nanion was founded in 2002 as a spin-off from the Center for Nanoscience (CeNS) of the University of Munich. Nanion's team has developed and successfully established four generations of automated patch clamp instruments for sophisticated and high throughput applications in ion channel research and drug discovery (Port-a-Patch, Patchliner and SyncroPatch product families). Further product lines are for cardiotoxicity screening (CardioExcyte 96), for parallel bilayer recordings (Orbit 16), and for parallel membrane transporter protein recordings (SURFE2R). Since 2014, Nanion distributes Axion's multi-electrode array (MEA) systems in Europe and China.

Contact details:
Dr. Niels Fertig, CEO, Phone: +49 89 2189 97972, Email: This email address is being protected from spambots. You need JavaScript enabled to view it.

Frank Henrichsen, Director of Global Sales, Phone: +45 40 87 29 17, Email: This email address is being protected from spambots. You need JavaScript enabled to view it.
Web: www.nanion.de

 

Dowload full press release here

See our photo gallery on the Opening Celebration here

 

 

13.01.2016 | Frank Henrichsen Appointed Director of Global Sales at Nanion Technologies

Munich, Germany, January 13, 2016; Nanion Technologies is pleased to announce that Frank Henrichsen has accepted the position of Director of Global Sales. Frank Henrichsen has a solid technical and commercial track record in life science industry, and is one of the pioneers in the global deployment of automated patch clamp systems in pharmaceutical companies and CROs.

Following the successful roll-out of the SyncroPatch 384/768PE, an advanced ion channel high throughput screening platform, Nanion is with the appointment of Frank Henrichsen as Global Sales Director, dedicated to further strengthening sales and customer support in the life science industry. During Henrichsen’s assignment as Vice President of Sales and Marketing at Sophion Bioscience, he was instrumental in building the company’s distribution network and customer base. Henrichsen’s extensive experience with sales management and automated patch clamping combined with his large network in the pharmaceutical industry make him ideally suited to further accelerate Nanion’s commercial success.

Dr. Niels Fertig, CEO of Nanion Technologies, says:

”Frank is not only a very dedicated and experienced professional with a profound background in technology commercialization, but also an expert in the automated patch clamp instrumentation business. He knows about ion channel screening from a customer requirement perspective, and how to meet and support customers! This combination together with his great personality makes him the ideal person to enhance Nanion’s commercial growth. During his tenure at Sophion, we at Nanion always respected his work tremendously, while at the same time appreciated his fair and sporty competition. I am delighted to welcome Frank to the team!”

Frank Henrichsen continues:

“I have followed Nanion closely since the company emerged in 2002. The Nanion team members have always impressed me with their dedication to science, their strength in rapid and continuous technical innovation and entrepreneurship and – not less – their always open and friendly attitude. In times where organizational changes, mergers and acquisitions are almost daily events, Nanion has demonstrated an unsurpassed organizational stability. It is easy to see how such stability can be transferred into intensified customer focus and continued product innovation. I really look forward to assist Nanion in further strengthening their commercial success while maintaining the company’s unique culture.”


About Nanion Technologies
Nanion Technologies was founded in 2002 as a spin-off from the University of Munich, Center for Nanoscience (CeNS). Over the last 14 years it has grown to a strong company with over 80 employees worldwide. Nanion has its headquarters in Munich, Germany, and has daughter companies in the USA, Japan and China, with distribution partners in 7 other countries. Nanion has been recognized for its quality and innovation by being twice nominated for the Federal President’s Award for Technology and Innovation (Deutscher Zukunftspreis) in 2007 and 2014. The company has become known for its high quality instruments for ion channel research (Port-a-Patch, Patchliner and SyncroPatch product families) and has over the years expanded its product range to include cardiotoxicity screening (CardioExcyte 96), parallel bilayer recordings (Orbit 16), and parallel membrane transporter protein recordings (SURFE2R). Since 2014, Nanion carries Axion’s multi-electrode array (MEA) systems in Europe and China.

Contact: 
Niels Fertig, CEO, Phone: +49 89 2189 97972, Email: This email address is being protected from spambots. You need JavaScript enabled to view it. , Web: www.nanion.de
Press contacts: Cecilia Farre, Marketing Director, Phone: +49 89 2189 979 73, Email: This email address is being protected from spambots. You need JavaScript enabled to view it.

Download the press release here.

 

11.01.2016 | New Nature Nanotechnology Publication: Orbit 16 Used for Exciting Research on Synthetic DNA Nanopores

Munich, Germany, January 11, 2016; Scientist from University College London and Nanion Technologies just published their work in Nature Nanotechnology, where the Orbit 16 was used to characterize synthetic DNA nanopores.

"A biomimetic DNA-made channel for the ligand-controlled and selective transport of small-molecule cargo through a biological membrane"
Jonathan R. Burns, Astrid Seifert, Niels Fertig, Stefan Howorka
11th January 2016, DOI: 10.1038/nnano.2015.279

Read the publication here.
Read the full press release here.

DNA ‘building blocks’ pave the way for improved drug delivery
DNA has been used as a ‘molecular building block’ to construct synthetic bio-inspired pores which will improve the way drugs are delivered and help advance the field of synthetic biology, according to scientists from UCL and Nanion Technologies.
The study, published today in Nature Nanotechnology and funded by the Biotechnology and Biological Sciences Research Council (BBSRC), Leverhulme Trust and UCL Chemistry, shows how DNA can be used to build stable and predictable pores that have a defined shape and charge to control which molecules can pass through the pore and when.

Lead author, Dr Stefan Howorka (UCL Chemistry), said: “Natural biological pores made of proteins are essential for transporting cargo into and out of biological cells but they are hard to design from scratch. DNA offers a whole new strategy for constructing highly specific synthetic pores that we can open and close on demand. We’ve engineered our pores to act like doors – the door unlocks only when provided with the right key. By building these pores into drug carriers, we think it will allow for much more precise targeting of therapeutics.”
Many therapeutics including anti-cancer drugs can be ferried around the body in tiny carriers called vesicles which are targeted to different tissues using biological markers. Previously, releasing the drugs from inside the vesicles was triggered with temperature-induced leaky vesicle walls or with inserted peptide channels, which are less rigid and predictable than DNA.
Using DNA building blocks, the team designed pores with pre-determined structures and defined properties which were precisely anchored into the walls – or membranes – of vesicles.
“Our pores take the shape of an open barrel made of six DNA staves. We designed a molecular gate to close off one entrance but then re-open the channel when a specific molecule binds. Anchors with high membrane affinity were attached to tether the water-soluble pores into the oily membrane,” explained first author, Dr Jonathan Burns (UCL Chemistry).
Using electrophysiology techniques, the researchers verified that the pore vertically spanned the surface of the membrane and was stable with an internal width of 2 nm, which is an appropriate size for small drugs molecules to fit through.

The gate’s lock and release mechanism was then tested with electrophysiology techniques as well as with fluorophores, which are of equivalent size to small molecules. As the DNA pore had a net negative charge, fluorophores with a net negative charge moved through with more ease than those with a net positive charge, showing selectivity for which cargo could exit. Removing the lock with a matching key increased of traffic 140-fold compared to a mismatched key.

Co-author Astrid Seifert who works with Dr Niels Fertig at Nanion Technologies, said: “We were able to precisely analyse the performance of each of the pores we created. We first inserted pores in membranes and then tested the biophysical response of each channel using advanced microchips. We’ve not only developed a new way to design highly specific pores but also an automated method to test their properties in situ, which will be important for testing pores being used for targeted drug delivery in the future.”
The researchers plan on testing the synthetic pores in a variety of scenarios including the release of anti-cancer drugs to cells and the development of pores that release pharmaceutically active biomolecules.

Dr. Howorka added, “Our approach is a big step forward in building and using synthetic biological structures and promises a new era in pore design and synthetic biology. We have demonstrated such precise control over the behaviour of the pore, both in terms of selectivity and in terms of responsiveness that we believe that the method paves the way for a wide range of applications from drug delivery to nanosensing.”


About UCL
(University College London) UCL was founded in 1826. We were the first English university established after Oxford and Cambridge, the first to open up university education to those previously excluded from it, and the first to provide systematic teaching of law, architecture and medicine. We are among the world's top universities, as reflected by performance in a range of international rankings and tables. UCL currently has over 35,000 students from 150 countries and over 11,000 staff. Our annual income is more than £1 billion. www.ucl.ac.uk  | Follow us on Twitter @uclnews  | Watch our YouTube channel YouTube.com/UCLTV

About Nanion Technologies
Nanion Technologies is a one-stop-shop for ion channel drug discovery and screening technologies as well as sophisticated research instrumentation. Nanion was founded in 2002 as a spin-off from the Center for Nanoscience (CeNS) of the University of Munich. Nanion’s team has developed and successfully established four generations of automated patch clamp instruments for sophisticated and high throughput applications in ion channel research and drug discovery. Product lines for cardiotoxicity screening, parallel bilayer recordings, and parallel membrane transporter protein recordings have also been successfully introduced. Since 2014, Nanion distributes Axion’s multi-electrode array (MEA) systems in Europe and China. In the published study Nanions Orbit 16 was used, a high quality platform for automated formation and recordings from 16 parallel bilayers. It facilitates efficient lipid bilayer recordings of ion channels or nanopores and their effectors. The Orbit uses the Micro Electrode Cavity Array (MECA) chip substrates, which are developed and provided by Ionera Technologies (www.ionera.de). www.nanion.de |

Follow us on: LinkedIn | www.Youtube.com/NanionTechnologies  

03.11.2015 | Nanion’s SyncroPatch is Preferred Technology for Patch Clamp-Based High Throughput Screening

Munich, Germany, November 3, 2015; According to a recent survey among automated patch clamp users, performed by HTStec Ltd., respondents favour Nanion’s instrumentation regarding cost, throughput, stability and support. Additionally, Nanion has the most appealing platforms for future purchase according to the survey.

With the introduction of the ion channel drug screening platform, the SyncroPatch 384/768PE, in 2013, Nanion became a major player in the high throughput screening (HTS) market. Nanion’s patch clamp-based HTS platform allows the screening of compound libraries of >100,000 substances, and facilitates a paradigm shift in drug discovery. Instead of indirect approaches of the past, compound effects can be efficiently and accurately investigated for drug discovery, lead optimization and safety testing purposes using patch clamp, saving valuable time and minimizing the risk of false positives or negatives.

In the recent HTStec report on automated patch clamp (APC) instrumentation, aiming to comprehensively document current practices, preferences and metrics in ion channel drug screening using APC technology, Nanion stood out as the favored APC vendor, with the most appealing platforms for future purchase.

Dr. Niels Fertig, CEO of Nanion Technologies, says:
“Since the launch of the SyncroPatch 384/768PE, there has been great interest in the platform, we clearly experience the market’s readiness for APC-based high throughput screening. We are very pleased with the outcome of the HTStec report, where the expanding installed base of our platforms confirms the trend presented in the report, and this not only in industrial settings. Contrary to what we initially expected, the SyncroPatch 384/768PE has also attracted academic scientists. The platform which will be installed at University College London later this month is one of multiple systems placed in a purely academic setting. This illustrates how versatility, high quality, and high throughput all coalesce in the SyncroPatch 384/768PE platform, making it attractive for both screening and research purposes.”

The SyncroPatch 384/768PE was developed in close collaboration with key customers in the pharmaceutical industry, and best-in-class robotics providers. This strategy has proven pertinent considering the quick development and roll-out, successful integration into HTS-environments and the rapidly growing installed base of the platform.

The HTStec Report is available from HTStec Ltd. (www.htstec.com).

About Nanion Technologies
Nanion Technologies was founded in 2002 as a spin-off from the University of Munich, Center for Nanoscience (CeNS). Over the last 13 years it has grown to a strong company with over 80 employees worldwide. Nanion has its headquarters in Munich, Germany, and has daughter companies in the USA, Japan and China, with distribution partners in 7 other countries. Nanion has been recognized for its quality and innovation by being twice nominated for the Federal President’s Award for Technology and Innovation (Deutscher Zukunftspreis) in 2007 and 2014. The company has become known for its high quality instruments for ion channel research (Port-a-Patch, Patchliner and SyncroPatch product families) and has over the years expanded its product range to include cardiotoxicity screening (CardioExcyte 96), parallel bilayer recordings (Orbit 16), and parallel membrane transporter protein recordings (SURFE2R). Since 2014, Nanion carries Axion’s multi-electrode array (MEA) systems in Europe and China.

 

Download the press release here.

 

 

11.08.2015 | New Genedata Ready-to-Run Delivers Out-of-the-Box Integration with Leading Screening Devices Intell iCyt , Labcyte, Nanion Technologies

Munich, August 11 2015; "New Genedata Ready-to-Run Delivers Out-of-the-Box Integration with Leading Screening Devices Intell iCyt , Labcyte, Nanion Technologies, and Thermo Scientific sign up as first partners for turnkey instrument integrations that effortlessly enable researchers to plug in new instruments to analysis pipelines.

Genedata, a leading provider of advanced software solutions for drug discovery and life science research, today announced that the first four partners have signed
on to its new Genedata Screener® Ready-to-Run program for turnkey integrations. Ready-to-Run integrations are instrument-specific, versioned, tested, and maintained by Genedata with the support of the respective instrument companies. Ready-to-Run gives researchers a fast and systematic way to import raw measurements from cutting-edge screening instruments. ...

Genedata Screener, which streamlines and standardizes data analysis, is the only software platform for end-to-end and fully integrated data analysis workflows in screening -- from raw data to the corporate data warehouse. Originally established for HCS, the Genedata Screener standard integration model is packaged in the Ready-to-Run program, which is now extended to High- Throughput Flow and Automated Patch Clamp (APC) technologies as well as liquid handling devices.
Nanion Technologies and Genedata have partnered for the first binary integration of an APC instrument with the screening data analysis workflow. Ready-to-Run integrations effectively overcome the gap between drug discovery data flows and data management infrastructure and screening instruments with their software. ..."

Prospective vendors may submit an inquiry to This email address is being protected from spambots. You need JavaScript enabled to view it.

About Genedata
Genedata transforms data into intelligence with a portfolio of advanced software solutions, which make research data accessible and understandable and research processes more efficient. These solutions are used worldwide by leading pharmaceutical, industrial, and agricultural biotechnology companies as well as academic research organizations. Genedata innovations enable scientific discovery that fights disease and improves health and quality of life worldwide. Founded in 1997, Genedata is headquartered in Switzerland, and has offices in Germany, Japan, and the US. www.genedata.com

Follow Us on LinkedIn

 

Download the full press release here.

17.07.2015 | From fundamental research to applications - CeNS Innovation Award 2015 for junior nanoscientists

censaw 200Munich, July 17 2015; On July 17, the CeNS Innovation Award was awarded at the Center for Nanoscience (LMU Munich) for the first time. One PhD student and one Master student received the award for their innovative work in application-oriented nanoscience. The awardees were selected by a top-class jury including amongst others Prof. Dr. Krubasik, president of the Deutsche Physikalische Gesellschaft. The award is worth € 9.000.

While most scientific prices emphasize on findings and results in fundamental research only, the CeNS Innovation Award decidedly attaches importance to future applicability. The prize money is donated by four successful spin-offs of CeNS, all with their own company history directly connected to the idea of the award. The companies attocube systems AG, ibidi GmbH, Nanion Technologies GmbH und NanoTemper Technologies GmbH together with CeNS honor gifted and creative junior researchers, whose results are not only interesting for fundamental research but also promising for technological applications.

ManziAurora Manzi from the group of Professor Jochen Feldmann (LMU) received an award worth € 3.000 in the category "Master's thesis". In her thesis, Aurora Manzi explored in cooperation with GE the usage of solar energy as an alternative to fossile fuels: She investigated the photocatalytic reduction of the greenhouse gas CO2 to methane, a valuable energy source. To this end, she developed an innovative, light-induced method to produce nanostructured semiconductors consisting of copper sulfide nanorods. These nanorods are capable of reducing CO2 to carbonmonoxide and methane under a broad visible light range. This method could contribute to developing efficient techniques for the transformation of solar energy into chemical energy sources. The 25 years old student, who originally comes from Italy, is currently continuing her academic career as a PhD student in Professor Feldmann’s group.

MastIn the category “PhD thesis“, the jury awarded the prize worth 6.000 EUR to Dr. Christof Mast from the group of Professor Dieter Braun (LMU). In his work Christof Mast could implement the amplification and self-enhancing, sequence-selective escalation of DNA length in a thermal trap for the first time. Due to minimal sample volumes, high sensitivity, and sequence selectivity, this method has the potential for rapid and continuous evolution of so called aptamers. Aptamers are short, single-stranded DNA or RNA molecules which specifically bind to targets and can thus selectively inactivate proteins within the cell. Thus, the technique developed by Christof Mast could contribute significantly to the faster development of targeted drugs. Dr. Masts’ results have been published in renowned scientific journals and in a patent specification.

The Center for NanoScience (CeNS) stimulates and coordinates research in the nanosciences in the Munich area. Since its foundation in 1998 at LMU Munich, CeNS has developed into a broad network of researchers from the LMU faculties of physics, chemistry, pharmacy, biology and medicine, including groups from TU Munich, the University of Augsburg, the Max Planck Institute of Biochemistry and other institutions in the Munich area.

 

logoContact
Dr. Susanne Hennig
Geschäftsführerin Center for NanoScience (CeNS)
LMU München
Geschwister-Scholl-Platz 1
80539 München
Tel.: +49-89-2180-5791
Fax: +49-89-2180-5649
This email address is being protected from spambots. You need JavaScript enabled to view it.  
www.cens.de

 

 

10.06.2015 | Team from Germany and France find new biological pore for polymer sizing

Freiburg, Germany, Cergy, France, June 10, 2015; In pioneering work carried out a decade ago in a collaboration between Oleg Krasilnikov and John J. Kasianowicz and coworkers, sizing of non-ionic synthetic polymers has been described as one of the most promising applications, besides DNA-sequencing, of ionic sensing with biological nanopores. In fact, only one type of nanopore and only one type of polymer has been used to demonstrate this principle, also called nanopore-based single molecule mass spectrometry (Np-SMMS): alpha-hemolysin, a heptameric beta.-barrel toxin from staph. aureus was used to establish the size distribution of polydisperse mixtures of poly(ethyleneglycol) (PEG).

Now, a team of researchers from Freiburg, Germany and Cergy, France, just published a paper in ACS Nano with the surprising finding that another pore-forming toxin, aerolysin from Aeromonas hydrophyla is much better suited than alpha-hemolysin to that purpose. The reason for the superior performance is the fact that over a potential range of 0 to 120 mV the dwell times of polymer-pore interaction in aerolysin show a strong increase with the strength of the electric field applied to drive the pore current and show a maximum at -120 mV (stem-side), with dwell times that are significantly longer than those found at the optimal potential for alpha-hemolysin (+40 mV). The work was carried out using the Orbit-16 automated bilayer device from Nanion Technologies GmbH running Ionera's MECA nanopore array chips.

Abdelghani Oukhaled, project leader for the French part of the team and one of the paper's senior authors says:
"Halfway through the collaboration on this paper, we took delivery of our own Orbit. If you have been fighting with bilayers for years, the ease of making a whole array of them and doing high-end recordings from them is a whole new world."

Gerhard Baaken who is first author and Ionera's CEO adds:
"It's a great experience to do interesting science and convince a future customer at the same time."

Jan Behrends of the Department of Physiology at Freiburg University and another senior author says:
"Aerolysin seems a very promising candidate not only for sensing synthetic polymers. In general, testing the interactions of various pores with various analytes seems a logical way forward to understand just what makes that interaction so sensitive to molecular size. It's a long road, but the throughput of the Orbit /MECA combination will help us to reach that goal."

Download the full publication here.

 

About Nanion Technologies
Nanion Technologies was founded in 2002 as a spin-off from the University of Munich, Center for Nanoscience (CeNS). Over the last 13 years it has grown to a strong company with over 80 employees worldwide. Nanion has its headquarters in Munich, Germany, and has daughter companies in the USA, Japan and China, with distribution partners in 7 other countries. Nanion has been recognized for its quality and innovation by being twice nominated for the Federal President’s Award for Technology and Innovation (Deutscher Zukunftspreis) in 2007 and 2014. The company has become known for its high quality instruments for ion channel research (Port-a-Patch, Patchliner and SyncroPatch product families) and has over the years expanded its product range to include cardiotoxicity screening (CardioExcyte 96), parallel bilayer recordings (Orbit 16), and parallel membrane transporter protein recordings (SURFE2R). Since 2014, Nanion carries Axion’s multi-electrode array (MEA) systems in Europe and China.

About Ionera Technologies
Ionera Technologies GmbH is a spin off from the University of Freiburg and was founded beginning of 2014. Ionera is a young startup company in the field of biophysical nanotechnology and develops and produces Micro Electrode Cavity Arrays (MECA) to allow automated and highly parallel recordings from lipid bilayers. The applications of this generic technology include electrophysiological studies of membrane protein properties as well as nanopore analysis e.g. polymer sizing with nanopores. Ionera is based in Freiburg, Germany.

Contact information

Dr. Gerhard Baaken, CEO Ionera Technologies GmbH, +49 761 203 5145 or This email address is being protected from spambots. You need JavaScript enabled to view it.

31.03.2015 | Nanion Technologies Appoints James Costantin as Director of Customer Relations

Livingston, NJ, USA, March 31, 2015; Nanion is pleased to announce the appointment of Dr. James Costantin as Director of Customer Relations at Nanion Technologies Inc. Dr. Costantin has a solid and highly impressive track record in customer relation management, in-depth knowledge of ion channel drug discovery, and over 12 years of technical expertise with automated electrophysiology platforms.

With the successful roll-out and rapidly growing installed base of the SyncroPatch 384/768PE, an advanced robotic ion channel high throughput screening platform, Nanion has expanded the US-team to increasingly focus on sales and customer support in this business segment. James Costantin has extensive experience in automated patch clamp (APC)-based ion channel drug discovery and has been instrumental in the development, deployment, and usage of automated patch clamp platforms. Rudi 3

Rodolfo Haedo, VP Nanion Inc., says:
“With the booming interest in the SyncroPatch 384/768PE and APC-based ion channel drug discovery from both pharma and academic laboratories, we anticipate another strong year for the SyncroPatch 384/768PE and we’re thrilled to have James Costantin on board. He is known for his dedication and customer focus, as well as for his profound knowledge and understanding of APC in drug discovery HTS applications. James is the perfect match for Nanion and with him on board, we’ll also strengthen our presence on the US-West coast.”

Dr. James Costantin continues:
Jim V2“Nanion is one of the few companies in this business showing exceptional stability and continuous dynamic company growth, they consistently have had a strong focus on technical product development and product management. I find the SyncroPatch 384/768PE platform to be extremely impressive due to its great technical capabilities, and with the new modular concept of integration into pre-existing robotic platforms, it is the only APC instrument that can rapidly be incorporated into fully automated HTS workflows. Nanion’s HTS-system paves the way for a new standard in APC-based ion channel screening and I’m quite pleased to join such a dedicated and dynamic team to serve our expanding customer base.”

 

About Nanion Technologies
Nanion Technologies was founded in 2002 as a spin-off from the University of Munich, Center for Nanoscience (CeNS). Over the last 13 years it has grown to a strong company with over 80 employees worldwide. Nanion has its headquarters in Munich, Germany, and has daughter companies in the USA, Japan and China, with distribution partners in 7 other countries. Nanion has been recognized for its quality and innovation by being twice nominated for the Federal President’s Award for Technology and Innovation (Deutscher Zukunftspreis) in 2007 and 2014. The company has become known for its high quality instruments for ion channel research (Port-a-Patch, Patchliner and SyncroPatch product families) and has over the years expanded its product range to include cardiotoxicity screening (CardioExcyte 96), parallel bilayer recordings (Orbit 16), and parallel membrane transporter protein recordings (SURFE2R). Since 2014, Nanion carries Axion’s multi-electrode array (MEA) systems in Europe and China.

 

Download the press release here.

 

10.02.2015 | Cardiac Researchers at National Heart Centre Singapore Acquire First SyncroPatch 384/768PE in Asia

Munich, Germany, February 10, 2015; Cardiac Researchers at National Heart Centre Singapore Acquire First SyncroPatch 384/768PE in Asia

The SyncroPatch 384/768PE is an advanced robotic screening platform that is used to investigate the effects of chemical compounds and toxins on ion channel function. The instrument supports high quality recordings from up to 768 cells simultaneously, allowing high throughput screening of ligand- and voltage-gated ion channels expressed in cell lines, stem cells or patient-derived cells. The SyncroPatch 384PE/768 PE combines high versatility and data quality by offering fast solution exchange, brief compound exposure, internal perfusion and minimal cell usage. The minimal cell usage application improves cost efficiency while allowing screening capabilities with cells of limited availability such as primary cells or otherwise rare and expensive stem cells or patient-derived cells. Nanion’s Patchliner, a high quality, automated patch clamp platform recording from eight cells in parallel, and the CardioExcyte 96, a 96-well plate based platform for contractility and electrical activity measurements from cellular networks, are acknowledged for their utility in cardiac safety and toxicity screening.

Dr. Winston Shim, Principal Scientist, National Heart Centre Singapore, says:
“I find the performance and technical capabilities of the SyncroPatch 384/768PE convincing. In particular, the fact that stem cell-derived cardiomyocytes can be measured with reasonable success rates, and the optimized cell handling procedure, which reduces input cell numbers, is appealing when working with patient-derived cardiomyocytes and other clinical samples. Additionally, Nanion’s Patchliner that supports automated current clamp recordings at physiological temperatures is highly attractive when investigating action potentials and drug-induced alterations. In combination with the CardioExcyte 96, it opens the possibility to investigate acute and chronic effects of chemical compounds on beating cardiac syncytium from our work on cardiac maturation. Going forward, I believe that such enabling platforms will galvanize our work in human cardiomyocytes from disease modeling to drug discovery and regenerative medicine.”

The CiPA initiative, commenced by HESI and the FDA, aims at expanding the mandatory cardiac ion channels from two to five in safety screening efforts, thus demanding higher throughput capabilities and the ability to use stem cell-derived cardiomyocytes in cardiotoxicity screening. Here, Nanion’s APC platforms the SyncroPatch 384/768PE and the Patchliner, constitute an excellent complement to the CardioExcyte 96 covering the range from in vitro cellular network studies to in-depth ion channel safety studies.

About Nanion Technologies
Nanion Technologies was founded in 2002 as a spin-off from the University of Munich, Center for Nanoscience (CeNS). Over the last 13 years it has grown to a strong company with over 80 employees worldwide. Nanion has its headquarters in Munich, Germany, and has daughter companies in the USA, Japan and China, with distribution partners in 7 other countries, including Singapore. Nanion has been recognized for its quality and innovation by being twice nominated for the Federal President’s Award for Technology and Innovation (Deutscher Zukunftspreis) in 2007 and 2014. The company has become known for its high quality instruments for ion channel research (Port-a-Patch, Patchliner and SyncroPatch product families) and has over the years expanded its product range to include cardiotoxicity screening (CardioExcyte 96), parallel bilayer recordings (Orbit 16), and parallel membrane transporter protein recordings (SURFE2R). Since 2014, Nanion carries Axion’s multi-electrode array (MEA) systems in Europe and China.

About Dr. Winston Shim, National Heart Centre Singapore
NDr Shim has extensive experience in cardiac electrophysiology and regenerative medicine for ischemia and heart failure. He was among the first in the world to demonstrate ex vivo differentiation of human mesenchymal stem cells into cardiomyocytes. His major interest is in cardiac developmental biology and physiology of human cardiomyocytes. His team has extensive experience in the generation of human induced pluripotent stem cells, characterization of human cardiomyocytes and cardiogenic pathways and his group conducts annual hands-on workshops for the stem cell community in Singapore. His group was the first to demonstrate restorative therapy for long QT syndrome 2 in human cardiomyocyte model. In his capacity as Principal Investigator of the National Heart Research Institute Singapore (NHRIS), he established the induced pluripotent stem cell program, cardiac tissue engineering program, regenerative medicine program and launched platform technologies in cardiac electrophysiology, experimental animal modelling, tissue and plastic histopathology, cardiac ultrasound and hemodynamic imaging to spearhead cardiac research in Singapore.

Contact
National Heart Centre Singapore, 9th Level, National Heart Research Institute Singapore, 5 Hospital Drive, Singapore 169609.

 

Download the press release here.

 

22.01.2015 | Nanion TWIns With Stem Cells as New Facilities Are Opened in Japan and USA

Tokyo, Japan and Livingston, NJ, USA, January 22, 2015; Nanion is expanding on two continents as new state-of-the-art research and demonstration facilities are opened in Tokyo, Japan and Livingston, NJ, USA. The new facilities provide the opportunity for customers to see Nanion’s entire product portfolio in action, from the Port-a-Patch to the SyncroPatch 384/768PE.

USA 306x288Nanion Technologies, an innovative German-based company providing high quality devices for ion channel research and drug discovery, recently expanded into new premises in both Japan and USA. Nanion Technologies Inc. opened in 2008 and due to expansion of personnel and devices it has now moved to larger premises in Livingston, NJ, with fully equipped laboratory facilities for validation experiments and demonstrations of the entire Nanion product range. Rodolfo Haedo, VP of Nanion Technologies Inc. says about the move:

Rodolfo Haedo, VP of Nanion Technologies Inc. says about the move:
”We are very excited to move to these new, larger and more modern premises. We have had huge interest in the SyncroPatch 384/768PE high throughput screening tool since its launch in 2013 and have an ever-increasing installed base of the instruments in the US. The SyncroPatch 384PE has been so well received by customers so far and we see a bright future for sales this year, as well as for our other Nanion instrumentation in the US. These new premises will give us the opportunity to exhibit our complete product range to its full potential”.

Japan 306x285In Tokyo, Japan, Nanion has opened a new research laboratory within the Tokyo Women’s Medical University - Waseda University Joint Institution for Advanced Biomedical Sciences (TWIns) . TWIns is a leading facility for induced pluripotent stem (iPS) cell research where Nanion has established a close collaboration with the Tokyo Women’s Medical University (TWMU) to combine the use of iPS cells on Nanion’s devices. Customers will be able to visit the facility to see the Nanion platforms in action with cells and receive high-quality support including iPS cardiomyocytes and neurons. Nanion Japan’s expert electrophysiologist and general manager, Atsushi Ohtsuki, says about the new premises:

“TWIns is a recognized institute for stem cell research with an excellent reputation. Our collaboration with TWMU will enable optimal performance of iPS cells on Nanion’s platform. We will have the full range of Nanion’s products available for scientific support or demonstrations in this new state-of-the-art facility in the heart of Tokyo, and look forward to welcoming both potential and existing customers to visit us here.”

About Nanion Technologies
Nanion Technologies is a one-stop-shop for ion channel drug discovery and screening technologies as well as sophisticated research instrumentation. Nanion was founded in 2002 as a spin-off from the Center for Nanoscience (CeNS) of the University of Munich. Nanion’s team has developed and successfully established four generations of automated patch clamp instruments for sophisticated and high throughput applications in ion channel research and drug discovery (Port-a-Patch, Patchliner and SyncroPatch product families). Further product lines are for cardiotoxicity screening (CardioExcyte 96), for parallel bilayer recordings (Orbit 16), and for parallel membrane transporter protein recordings (SURFE2R). Recently, Nanion’s management team was nominated for the Federal President’s Award for Technology and Innovation (Deutscher Zufunftspreis 2014).

 

Download the press release here.

 

15.10.2014 | Prestigious Academic Facility at Northwestern University Acquires the SyncroPatch 384/768PE

Livingston, NJ, USA, October 15, 2014; The SyncroPatch 384/768PE offers the highest throughput in automated patch clamping history. The SyncroPatch 384/768PE focuses on providing both high quality recordings together with broad experimental versatility, two important hallmarks that clearly convinced scientific researchers at the Northwestern University Feinberg School of Medicine, Chicago, IL.

The SyncroPatch 384/768PE is an advanced robotic screening platform that investigates the effects of chemical compounds and toxins on ion channel function. The instrument supports high quality recordings from up to 768 cells simultaneously, allowing high throughput screening of ligand- and voltage-gated ion channels expressed in cell lines, stem cells or patient-derived cells.
The SyncroPatch 384PE/768 PE combines high versatility and data quality by supporting fast solution exchange, brief compound exposure, internal perfusion and minimal cell usage. The minimal cell usage application improves cost efficiency while allowing screening capabilities with cells of limited availability such as primary cells or otherwise rare and expensive stem cells or patient-derived cells. Entering the market in 2013, the SyncroPatch 384/768PE was rapidly adopted by renowned pharmaceutical companies, contract research organizations and biotech companies, following a strong trend which includes academic research institutions. Academic core facilities have blossomed all across America over the past years, providing researchers with the ability to run high throughput and high content screens for drug or target discovery that not too long ago was strictly exclusive to Big Pharma and biotech companies. By blending the strength and standardization of Big Pharma with the intelligence and acumen of basic research, core facilities can now contend with more ambitious projects that call for larger resources.

Dr. Al George, Professor and Chair of Pharmacology at Northwestern University Feinberg School of Medicine, Chicago, IL, USA says:
“We are extraordinarily excited about installing the first SyncroPatch 384PE in an academic setting in North America. The enormous throughput, intuitive software and robust liquid handling capabilities along with superior seal quality, stability and high success rates convinced us to purchase the instrument. The SyncroPatch 384PE will enable us to perform detailed high throughput analysis of genetic variants in human ion channels at a previously unobtainable scale, and will form the cornerstone of a new HTS facility we are building. We also look forward to upgrading to 768 wells in the near future.”

Rodolfo Haedo, Vice President Nanion Technologies Inc. continues:
“The acquisition of the SyncroPatch 384/768PE by the prestigious facility at Northwestern University Feinberg School of Medicine confirms the trend we’re experiencing, that the SyncroPatch 384/768PE is receiving a great deal of attention by the finest scientific research laboratories in the world. We are extremely excited to work with Dr. George and the groups involved at Northwestern University as they work at the interface of ion channel pharmacology and channelopathy research. We will finally have the opportunity to see the implementation of many different applications, ranging from hard-core biophysical characterization of patient-specific ion channel mutations, as well as target directed drug screening for personalized medicine, which in turn will continue to push the boundaries of what to expect from a patch clamp-based HTS system.”

About Nanion Technologies
Nanion Technologies is a one-stop-shop for ion channel drug discovery and screening technologies as well as sophisticated research instrumentation. Nanion was founded in 2002 as a spin-off from the Center for Nanoscience (CeNS) of the University of Munich. Nanion’s team has developed and successfully established four generations of automated patch clamp instruments for sophisticated and high throughput applications in ion channel research and drug discovery (Port-a-Patch, Patchliner and SyncroPatch product families). Further product lines are for cardiotoxicity screening (CardioExcyte 96), for parallel bilayer recordings (Orbit 16), and for parallel membrane transporter protein recordings (SURFE2R). Recently, Nanion’s management team was nominated for the Federal President’s Award for Technology and Innovation (Deutscher Zufunftspreis 2014).

About Northwestern University Feinberg School of Medicine
Northwestern University Feinberg School of Medicine, founded in 1859, attracts talented individuals to its faculty, staff, and student body through its cutting-edge research initiatives, superb clinical affiliates, global outlook, and innovative curriculum. Located in the heart of Chicago’s Magnificent Mile, Feinberg has built a national reputation for excellence through a strong history of collaborative, interdisciplinary medical education and research, and along with Northwestern Memorial Hospital and Northwestern Medical Group is part of the premier academic medical center known as Northwestern Medicine. Feinberg stands out among the nation's research-intensive medical schools and consistently receives high marks in U.S. News & World Report surveys. Through its affiliates, it provides patient care to thousands of individuals every year, and plays an integral part in the communities it serves.

Dr. George is the Magerstadt Professor and Chairman of Pharmacology and Director of the Center for Pharmacogenomics at Northwestern University Feinberg School of Medicine. He is an internationally regarded leader of diseases caused by the disturbed function of ion channels (channelopathies), including those resulting in heart rhythm disorders, such as the congenital long-QT syndrome, and neurological disorders, including epilepsy.

 

Download the press release here.

 

17.09.2014 | The Team Behind Nanion Technologies Nominated for the Deutscher Zukunftspreis– the Federal President’s Award for Technology and Innovation

Munich, Germany, September 17, 2014; The management team at Nanion Technologies is one of three nominees for the Deutscher Zukunftspreis, the German president’s award for technology and innovation. As announced today, the team has been nominated for Nanion’s latest automated screening platform, the SyncroPatch 384/768PE, which enables completely new strategies in drug discovery and scientific research.DZP Logo Zusatz-03DZP 2014 Team1 web2330x470

As one of the leading industrial nations, Germany is known for its strength in technical innovation and entrepreneurship with a strong focus on product quality. The Deutscher Zukunftspreis (German Future Award), by which the German Federal President rewards cutting-edge technological innovations, which also have a high potential for commercial success and societal benefit, is the country's most prestigious award for technology and innovation.

At a press conference in Munich today, the Office of Federal President Joachim Gauck announced the nomination of Nanion Technologies' management team for the development and successful market entry of the SyncroPatch 384/768PE, a chip-based platform allowing high throughput screening of compounds affecting ion channels. Ion channels are proteins residing in the membranes of cells of the human body. Because ion channel dysfunction underlies diverse diseases and their symptoms, they are highly important both from the basic biomedical science and drug development stand point. The SyncroPatch 384/768PE is the first platform ever to allow functional ion channel screening on a truly industrial scale, with novel possibilities and great potential of bringing new and safe medication to the market faster. Dr. Niels Fertig (CEO), Dr. Andrea Brüggemann (CSO), and Michael George (CTO) are the team behind the project “High Throughput Ion Channel Screening – from the University Bench to Global Player” nominated for this year’s Deutscher Zukunftspreis.

Dr. Niels Fertig, spokesperson, co-founder and CEO of Nanion Technologies, says:
We are thrilled and feel very honoured to be nominated for the most prestigious award for technology and innovation in Germany, and we look forward to the great event in Berlin where the award winning team will be announced. Of course we’re biased, but the SyncroPatch 384/768PE clearly has great potential to revolutionize ion channel screening, thus enabling biotech and pharma companies to bring better drugs to the market at a faster pace.

The final winner will be selected by the jury on November 19 in Berlin and will be announced on the evening of that day by Federal President Joachim Gauck, at a major event hosted and broadcasted by the public television channel, ZDF.

 786peBiomek

 

 

 

 

 

 

 

 

 

 

 

About Nanion Technologies

Nanion Technologies is a one-stop-shop for ion channel drug discovery and screening technologies as well as sophisticated research instrumentation. Nanion was founded in 2002 as a spin-off from the Center for Nanoscience (CeNS) of the University of Munich. Nanion’s team has developed and successfully established four generations of automated patch clamp instruments for sophisticated and high throughput applications in ion channel research and drug discovery (Port-a-Patch, Patchliner and SyncroPatch product families). Further product lines are for cardiotoxicity screening (CardioExcyte 96), for parallel bilayer recordings (Orbit 16), and for parallel membrane transporter protein recordings (SURFE2R). Since 2014, Nanion carries Axion’s multi-electrode array (MEA) systems in Europe and China.

Download the full press release here.

Download the press release in German here.

Go to Deutscher Zukunftspreis official webpage here.

Information and material for the press here.

 

Image copyright Ansger Pudenz Deutscher Zukunftspreis 2014

01.09.2014 | Nanion’s Port-a-Patch Convinces Researchers at the Woods Hole and Cold Spring Harbor Summer Programs

Livingston, NJ, USA, September 1st, 2014; Nanion visits the prestigious scientific summer programs at the Marine Biological Laboratory in Woods Hole and at Cold Spring Harbor Laboratory, NY, to show the versatility and ease-of-use of the Port-a-Patch. Students and lecturers were very impressed by how the Port-a-Patch makes high quality patch clamp recordings accessible to the user with minimal training.

The Marine Biological Laboratory (MBL) in Woods Hole, MA and the Cold Spring Harbor Laboratory (CSHL), NY, are world famous institutions in the biosciences spawning Noble-price winning research. Every year a number of prestigious summer programs are hosted, some of the best students and instructors from the USA and around the world gather to further their training and to exchange ideas. This year Nanion was invited to both the Neurobiology course at the MBL (co-directed by Professors Dr. Grame Davis of UCSF and Dr. Timothy A. Ryan of Cornell University) and the Ion Channels and Synaptic Transmission Course at CSHL (co-directed by Professors Dr. Stephan Brenowitz, NIDCD/National Institutes of Health, Dr. Ian Duguid, University of Edinburgh, UK, and Dr. Paul Kammermeier, University of Rochester, USA). Application scientist Dr. George Okeyo and Head of US Lab Operations Dr. Joerg Oestreich, both from Nanion Technologies Inc., ventured out with the Port-a-Patch to demonstrate the versatility and ease-of-use offered by Nanion’s automated patch clams systems. At both institutions, students and instructors alike were impressed with the Port-a-Patch for its ease of use. Here is what some of the participants had to say:

Dr. Bautista, UC Berkeley, teaching the electrophysiology section in the neurobiology class at MBL said:

"We are extremely happy about the performance of the Port-a-Patch. We used it for two weeks and very easily trained all the students in the course on it. We had a very high success rate when it came to patching transfected HEK cells, and also managed to obtain recordings from freshly dissociated mouse DRG neurons. We want to thank you again for lending us your instrument, everybody was very impressed."

Dr. Kammermeier at Cold Spring Harbor Laboratory (CSHL), NY, remarked:

"Thanks for visiting the Ion Channels and Synaptic Transmission course this summer at the Cold Spring Harbor Laboratory. The course participants enjoyed your demonstration of the Port-a-Patch system and were impressed that you were able to set up and get some recordings in such a short time frame. I can see how this system can be useful, particularly in the simple intracellular solution exchange, something that cannot be so easily done with conventional patch-clamp recording. I think this system may reduce the learning curve for new students to acquire some data, which could allow graduate students doing short lab rotations to get their feet wet quickly in a patch-clamp lab."

Dr. Amy Lee, Associate Professor in the Departments of Molecular Physiology & Biophysics, Otolaryngology Head-Neck Surgery, University of Iowa, and guest lecturer at the CSHL course:

"Building an electrophysiology rig is a daunting task for the investigators with little experience with patch-clamp recording techniques. The Port-a-Patch simplifies the task, and allows entry-level patch clampers to obtain high-quality electrophysiological data from a variety of cell-types. With its tiny footprint, the Port-a-Patch is also an excellent solution for small laboratory spaces. Due to the ease with which recordings can be performed, the Port-a-Patch would be ideal for demonstrating general concepts on membrane excitability to students in the teaching or research lab."

Image Round V1

 


Port-a-Patch in action at the Neurobiology Course at MBL in Woods Hole. Patch clamp recordings were made on the Port-a-Patch from acutely dissociated neurons. Data courtesy of by Dr. Diana Bautista and Mr. Pellegrino.

 

by Joerg Oestreich

17.06.2014 | Nanion Technologies and Axion Biosystems Announce Strategic Distribution Partnership in Europe and China

Munich, Germany, June 17, 2014; Nanion Technologies, a leading provider of automated patch clamp platforms, and Axion Biosystems, originator of the first high throughput microelectrode array system, today announce a distribution partnership in Europe and China. Nanion will immediately carry Axion’s MEA-products, supporting a broad range of biomedical applications.

Axion Biosystems provides state-of-the-art, high resolution, MEA based instruments for experiments ranging from basic cellular electrophysiology to high throughput screening (HTS). Axion’s MEA systems represent the next generation in multielectrode array technology, providing unprecedented access to native cellular electrical signaling and connectivity. To meet the growing demand for “disease in a dish” assays and functional safety screening, Axion and Nanion today announced a strategic distribution partnership for the European and Chinese markets.
Further strengthening and complementing the Nanion product portfolio, Nanion will distribute, service, and support the Axion single-well MEA system, the Muse, and the Maestro, a multiwell MEA system with HTS capabilities.

Dr. Niels Fertig, CEO and founder of Nanion Technologies, says: “We are extremely impressed by Axion’s MEA-systems because of their broad scope of applications, ranging from in-depth, highly resolved cellular network behavior to high throughput drug screening. We think that Axions’s products provide an excellent complement to our automated patch clamp screening and impedance-based systems, and see great potential for applications including phenotype screening, stem cells as tools for phenotypic disease models, and of course, safety, neuro- and cardiotoxicity testing. Additionally, the partnership with Axion will further strengthen us as the one-stop-shop for proficient tools for electrophysiology drug research, screening and intersecting areas.”

Tom O’Brien, CEO of Axion Biosystems, continues: “Nanion is a great match for Axion, since we share the same background and philosophy, ultimately manifested in innovative products. As companies, we both have a solid research- and application-driven focus, as well as a deep understanding and broad expertise in science and technical development. These characteristics are combined with a vision to push the boundaries toward HTS-compatible products. We were attracted to Nanion’s strong track record of growth, and their excellent reputation for customer service and product reliability. We are excited about this partnership and have great confidence that Nanion will be very successful as our sales and distribution partner for the European and Chinese markets.”

Nanion Technologies and Axion Biosystems will be displaying their products together at the MEA-meeting in Reutlingen, Germany, July 1-4, 2014, and at the FENS 2014 meeting in Milan, Italy, July 4-7, 2014.

Download the full press release here.

Visit the products page here.

For a demonstration or a quote on the Maestro, Muse or consumables, please contact us at This email address is being protected from spambots. You need JavaScript enabled to view it. !

Go to Axion Bioystem's website here.

25.04.2014 | Nanion receives New Jersey Business Incubation Network’s Award 2014

North Brunswick, NJ, USA, April 25, 2014; Out of 325 startup companies in NJ, Nanion was selected for NJBIN award and recognized as one of the highest performing companies in the area. The New Jersey Business Incubation Network is a collaborative statewide community of business experts and resource facilities dedicated to enhancing the commercial success of early stage and expansion stage entrepreneurial companies, growing higher paying jobs, and supporting the economic growth strategy for the state.

Rodolfo Haedo, Vice President Nanion Technologies Inc., says:

I want to thank the NJBIN and CCIT for nominating us for this award and for the hard work of the US-team allowing us to be here today. We are honored to accept this award!

Rodolfo Haedo and Joerg Oestreich, Head of US Lab Operations, accepted the NJBIN Award at ceremony on April 25, 2015, held at Rutgers EcoComplex in Bordentown, NJ.

 NJBIN2014 V2

Rodolfo Haedo thanking for the NJBIN Award, watch the video here:

Rudi Utube

 

11.02.2014 | Successful Introduction of a Novel Patch Clamp-Based HTS-System Through Collaboration Between Nanion and Beckman Coulter

Munich, Germany, February 11, 2014; Nanion recently introduced the SyncroPatch 384 Patch Engine (PE), an instrument for HTS-compatible ion channel screening. As a modular part of the Biomek FX, a state-of-the-art liquid handling robot from Beckman Coulter, the SyncroPatch 384PE allows stable and reliable recordings and ensures swift setup and integration into existing HTS-environments.

Patch clamp is the gold standard for investigating ion channels and their effectors, but is remotely far from high throughput screening (HTS) standards. During the past decade, great efforts have been made to automate the patch clamping process and thereby overcome its ultra-low throughput, resulting in a handful of medium-throughput automated patch clamp systems.

Last year the SyncroPatch 384PE was introduced, the first instrument capable of delivering high quality patch clamp data in a 384-well plate format, accompanied by the complete automation of ion channel screening. In this way, the SyncroPatch 384PE allows full integration into HTS-related software, hardware and processes.

By teaming up with Beckman Coulter, a provider of best-in-class liquid handlers, Nanion could focus solely on the development of the Patch Engine, a patch clamp module with 384 parallel recording channels. Two Patch Engine modules can be integrated per Biomek FX robot, together offering stable whole cell recordings from up to 768 cells in parallel, with average success rates of 85% for completed experiments. The system allows for at least 20,000 data points per day, and is well-suited for both ligand- and voltage-gated ion channels.

 Dr. Christoph Krüll, Marketing Manager EMEAI, Life Science Automation, Beckman Coulter GmbH, says:

The Biomek FX is a great match for the SyncroPatch 384PE because of its robustness, flexibility and the fact that it is common throughout laboratories worldwide. Additionally, Beckman Coulter’s open software architecture ensures complete integration of SyncroPatch 384PE control functions, facilitating simple and straightforward setup of schedules and routines. The SyncroPatch 384PE provides for an application specific Biomek system and expands the area of use for our products.”

 Dr. Niels Fertig, CEO and founder of Nanion Technologies, continues:

“The development of the Patch Engine was extremely rapid and relies on proven successful technology and more than 10 years’ experience in product development of automated patch clamp devices. But in addition, the quick development, recent launch and shipping of the system, was to great extent accomplished by using the Biomek FX as primary liquid handling platform. The Biomek FX offers advanced and reliable pipetting options, massively parallel pipetting heads, and the complete integration into existing control software. So for Nanion, most of the liquid handling requirements were a “consider-it-done”-situation with Beckman Coulter as partner.”

Nanion’s team of application specialists and support technicians work closely together with Beckman Coulter’s global service network, for a swift and seamless integration of the SyncroPatch 384PE into existing HTS environments and to promptly respond to customer requests.

The SyncroPatch 384PE will be displayed at the Biophysical Society’s annual meeting in San Francisco, CA, February 15-19.

 

About Nanion Technologies:

Nanion Technologies GmbH is a German Private Limited Company and was founded in 2002 as a spin-off from the Center for Nanoscience (CeNS) of the University of Munich. Nanion’s team has developed and globally established four generations of highly successful automated patch clamp instruments as enabling tools for sophisticated and high throughput applications for ion channel research and drug discovery. Nanion recently launched the CardioExcyte 96, for cardiac safety screening, and the SURFE2R N96, a device for parallel membrane transporter protein recordings.

Contact:

Niels Fertig, CEO, Phone: +49 89 2189 97972, Email: This email address is being protected from spambots. You need JavaScript enabled to view it. , Web: www.nanion.de

 

About Beckman Coulter

Beckman Coulter Life Sciences’ global leadership and world-class service and support delivers instrument systems, reagents and services to improve workflow and outcomes for researchers in academic and commercial life sciences laboratories, enabling discoveries in biology-based research and development, and solutions for bioprocessing. A leader in centrifugation and flow cytometry, Beckman Coulter also has brought to market innovations in capillary electrophoresis, particle characterization and laboratory automation. Its products are used to further important areas of scientific investigation, including genomics and proteomics.

For more information, please visit www.BeckmanCoulter.com.

Beckman Coulter, the stylized logo, and Biomek are trademarks of Beckman Coulter, Inc. and are registered in the USPTO.

Press Contact:

Hillary Hunter
Public Relations
Beckman Coulter Public Relations

This email address is being protected from spambots. You need JavaScript enabled to view it.

+1 (561) 714-7826

17.10.2013 | Port-a-Patch in Education - Promotes Intriguing Neuroscience Research for Undergrad Students at Cedar Crest College

The Port-a-Patch is often referred to as the world’s smallest patch clamp set-up. It is so small that it can be held in one hand, and at the same time a very powerful and enabling technology with a vast experimental freedom. Port-a-Patch makes patch clamping easier and offers about a tenfold throughput increase compared with the conventional set up. The learning curve is steep, thus allowing patch clamp also in shorter projects.

Dr. Audrey Ettinger, Director of the Neuroscience Program at Cedar Crest College, has recently invested in a Port-a-Patch for teaching and for neuroscience research projects, intending to investigate the effect of herbal substances as neuroprotective agents in diseases such as stroke. Dissociated neurons from developing chick will be used as model in this study.

Below are excerpts from the Cedar Crest College press release, as well as a link to the full press release.

 

Allentown, Pa. (September 13, 2013) - The National Science Foundation awarded a $186,032 grant to Cedar Crest College that will give biology students the opportunity to work with top-of-the-line instrumentation, providing a competitive edge in the marketplace post-graduation. Associate Professor and Director of the Genetic Engineering Program, K. Joy Karnas, Ph.D., and Associate Professor and Director of the Neuroscience Program, Audrey Ettinger, Ph.D., submitted the proposal to provide their students access to the latest experimental technology and to increase opportunities to collaborate with neighboring colleges and universities in the Lehigh Valley and beyond. This is the first grant that Karnas and Ettinger have received from the National Science Foundation.”

“In August, representatives from Nanion Technologies installed the Port-a-Patch, a miniaturized patch clamp system that generates cell physiology data quickly and easily. Cedar Crest students will waste no time in utilizing this new technology, as Karnas and Ettinger already have specific research questions in place that students will begin exploring this fall. Students will be investigating the role of herbal remedies as neuroprotective agents for neurons in diseases such as stroke (the third leading cause of death in the United States). Students working under the direction of Ettinger will use dissociated neurons from developing chick embryos to chemically simulate stroke, and then attempt to rescue those neurons using an herbal remedy such as Ginkgo biloba extract. They will study the cells using fluorescence microscopy, and use the newly obtained Port-a-Patch instrument to examine ion channels in those cells.”

 

Read the full press release here.

More information about the Port-a-Patch here.

More Port-a-Patch data here.

08.10.2013 | Joint Press Release: Tecella Powers Nanion's SyncroPatch 384PE

FOOTHILL RANCH, CA (Oct 8, 2013) - Nanion selected Tecella's Mach amplifier to power their SyncroPatch 384PE automated patch clamp system. The SyncroPatch 384PE (Patch Engine) is the industry's highest throughput giga-seal system scalable to 768 channels, and is capable of 20,000 data points per day.

"The Mach significantly reduced the time-to-market for the SyncroPatch 384PE", states Niels Fertig, Nanion CEO. "With Tecella's technology, we are able to deliver a fully parallel system configured as 384-channels or 768-channels."

With throughput of 20,000 data points per day, the SyncroPatch 384PE aims to accelerate the drug discovery process by enabling high-quality ion channel recordings to be performed during primary screening.

Nanion's SyncroPatch 384PE will be displayed at the Society for Laboratory Automation and Screening (SLAS) 2014 Conference in San Diego from January 18-22, 2014.

Product information: http://www.nanion.de/products/syncropatch-384pe.html

About Tecella
Tecella specializes in the development of patch clamp amplifier systems and digitizers for the advancement of drug discovery. For inquiries regarding this press release, Tecella, please contact:

Dianne Yamamoto, Business Manager

Phone: +1-714-641-1709, E-mail: This email address is being protected from spambots. You need JavaScript enabled to view it. , Web: www.tecella.com

About Nanion
Nanion Technologies GmbH is a German Private Limited Company and was founded in 2002 as a spin-off from the Center for Nanoscience (CeNS) of the University of Munich. Nanion’s team has developed and globally established three highly successful automated patch clamp instruments as enabling tools for sophisticated and high throughput applications for ion channel research and drug discovery.

Nanion recently launched the CardioExcyte 96, for cardiac safety screening, and the SURFE2R N96, a device for parallel membrane transporter protein recordings.

Contact details:

Niels Fertig, CEO, Phone: +49 89 2189 97972, Email: This email address is being protected from spambots. You need JavaScript enabled to view it. , Web: www.nanion.de

Cecilia Farre, Marketing Director, Phone: +49 89 2189 979 73, Email: This email address is being protected from spambots. You need JavaScript enabled to view it.

24.09.2013 | Nanion Starts Shipping the SyncroPatch 384 Patch Engine – a Revolutionary Instrument for Giga-Seal, Automated Patch Clamp-Based Ion Channel Drug Screening

Munich, Germany, 24.9.2013; The brand-new SyncroPatch 384 Patch Engine (PE) now released by Nanion Technologies propels ion channel drug discovery to a new level. Designed for seamless integration into process-automated drug screening environments, the Patch Engine is equipped with 384 patch clamp amplifiers and an advanced 384 channel liquid handling robot.

The SyncroPatch 384PE is the high quality, automated patch clamp system able to finally thrust gold standard electrophysiology from secondary to primary ion channel drug screening. Allowing for up to 20,000 data points per day, it is the most efficient platform on the market for high quality, ion channel recordings. This efficiency is primarily due to fully parallel measurements from 384 cells, the 384-channel pipettor, and an exceptionally efficient control and analysis software. Both hardware and software have been fully tested and validated with leading players in industrial ion channel drug development to provide optimum performance in true HTS for ion channel screening. In contrast to prior automated patch clamp devices, which are stand-alone machines, the Patch Engine is a modular approach specifically designed for integration with all aspects of process-automated screening environments. Up to two of the 384 channel patch clamp modules can be integrated into one liquid handling robot, enabling 768 recording wells to be measured simultaneously. Success rates are routinely over 85%, and liquid consumption is low. A full run of 384 cells for dose response analysis takes less than 15 minutes, delivering several thousand data points per hour.
 Dr. Niels Fertig, CEO of Nanion says:

“The SyncroPatch 384PE is a landmark in the history of automated patch clamping. It follows a completely revolutionary concept: a truly modular and HTS-capable automated patch clamp device that will integrate into your existing or planned screening process line, rather than being a closed, stand-alone system. No other platform on the market is capable of recording 384 to 768 cells in parallel, let alone with giga-seals. In development, we have carefully listened to key customers from industrial pharma high throughput screening laboratories to fulfil their requirements of HTS-settings. We are extremely excited and enthusiastic about our new platform, and so are the first customers who recently invested in several SyncroPatch PE instruments. We are happy to announce that we are now taking orders for delivery in 2013 of this maturely developed and fully validated platform.”

The SyncroPatch 384PE has successfully been validated with a wide variety of different cell types and ion channels, with consistently high performance regarding seal quality and stability. The excellent success rates and cell-stability promote efficient and reliable drug screening, thus minimizing the need of replicate experiments.

The SyncroPatch 384PE is now fully available for sale, with the first systems being shipped during the coming month.

 

For more information about the SyncroPatch 384PE, click here.

For the full press release, click here.

 

PresseEcho.de

12.09.2013 | Nanion Introduces New Product Family: CardioExcyte 96 for Cardiac Toxicity Profiling and Screening

Munich, September 12,2013, The CardioExcyte 96 is a high resolution device recording contractility in intact cardiomyocyte networks utilizing non-invasive impedance measurements. The system allows cost-efficient, early compound safety profiling using stem cell-derived cardiomyocytes, freshly dissociated cardiomyocytes or beating 3D-cell clusters.

Cardiac safety assessment is a vital part of drug development since late withdrawals of compound candidates, due to heart liability issues such as ventricular arrhythmia, are very costly. In-vivo methods give highly relevant information but are extremely low throughput allowing the analysis of only a handful of compounds. In-vitro methods, such as automated patch clamp and other methods, offers higher throughput, however from one type of cardiac ion channels, typically over-expressed in cell lines. Nanion’s new device, the CardioExcyte 96, has the potential to bridge this gap, by allowing reliable label-free measurements of short- and long-term compound effects on the beating pattern of stem cell-derived cardiomyocytes. The system offers the highest impedance time-resolution (sub-millisecond) on the market and records from 96 wells in parallel. Efficiency and ease-of-use are facilitated by an outstanding software package for data handling and export; thus an essential part of the CardioExcyte system.

 Dr. Sonja Stölzle-Feix, Senior Scientist, Nanion Technologies, Munich, says:

“CardioExcyte 96 is an easy-to-use system, providing impedance-based cardiac safety data from a diversity of stem cell-derived cardiomyocytes. Concentration- and time-dependence of a compound’s potential cardiotoxicity can efficiently be obtained. Further on, the powerful software, used for recordings and analysis, employs comprehensive beat investigation algorithms, displaying detailed beating kinetics in real-time. Data handling and export is straightforward, easy to grasp and yet very, very powerful.”
 Dr. Niels Fertig, CEO of Nanion continues:

“CardioExcyte is a new branch in Nanion’s product portfolio. This label-free impedance system constitutes an excellent complement to automated patch clamp-based safety screening. It offers cost-efficient and highly relevant data on a drug candidate’s effect on intact networks of beating heart cells. Alteration of beating patterns can give a hint on what cardiac ion channel is affected, which is where detailed electrophysiology investigations take on the further investigations. Cardiac network responses offer a comprehensive view of a compound’s safety profile, without having to use in-vivo methods, and thus save time, costs and suffering.”

 The CardioExcyte 96 is an automated device, recording from 96 wells at a time. With embedded electronics and a sophisticated sensor technology inside the well-plate based consumables, CardioExcyte 96 is a turn-key system for efficient impedance measurements, also allowing recordings residing inside of the incubator. The system has been validated with stem cell derived cardiomyocytes from several providers (Axiogenesis, Cellular Dynamics International, GE Healthcare), as well as beating, 3D-clusters (Cellectis).

 

For more information about the CardioExcyte 96, click here.

For the full press release, click here.

 

PresseEcho.de

29.11.2012 | Nanion's automated bilayer platform Orbit 16 and Ionera's MECA bilayer array enable the functional analysis of synthetic DNA-based nanopores

Munich & Freiburg, Germany, November 29, 2012; In a landmark publication in Science2, research on artificially designed DNA-origami nanopores has been published this week using Nanion's new ORBIT 16 platform running Ionera's MECA1 bilayer array chip. The team of Prof. Simmel from the Technical University Munich has created nanometer-scale transmembrane ion channels by means of self-assembled DNA-based nanostructures. These “designer pores” have been reconstituted in lipid bilayers for functional characterization using the Orbit 16 for automated formation of, and recordings from 16 bilayers in parallel on Ionera's MECA1 array.

Recently, interest in using ion channels as molecular Coulter counters or nanopores for analytical techniques has strongly grown. The ORBIT platform, running the MECA bilayer array, is an enabling element for nanopore research and ion channel reconstitution. In the ground-breaking work of Simmel et al., published in the current issue of Science2, artificial ion channels have been designed based on DNA origami nanostructures. This technique employs DNA molecules as programmable building materials for custom-designed, self-assembling, nanometer-scale structures, basically allowing for the design of the complex structures on a standard computer. The researchers present evidence that their nature-inspired nanostructures may also behave like biological ion channels. They indeed show for the first time the potential for functional use of DNA nanotechnology in applications of synthetic membrane channels as molecular sensors, antimicrobial agents, and drivers of novel nanodevices.

To test one potential application, the researchers used them as nanopores for several different molecular sensing experiments. These confirmed that it is possible, by observing changes in the electrical characteristics, to record the passage of single molecules through synthetic membrane channels made from DNA. Because this approach allows both geometric and chemical tailoring of the membrane channels, it might offer advantages over two other families of molecular sensors, based on biological and solid-state nanopores respectively.

This new type of highly exciting "designer nanopores" has been efficiently and precisely analysed with the automated bilayer recording platform from Nanion. The Orbit 16 employs recording chips containing a microelectrode cavity array (MECA) provided by Ionera, a spin-off project from the University of Freiburg and speeds up the entire analytical process by the rapid and simultaneous formation of 16 highly stable micrometer-sized bilayers for parallel analysis. To automatically and simultaneously form bilayers on all 16 cavities, the Orbit uses a proprietary method (Ionera-SPREAD) which essentially is a 100%-yield, no-waiting time automated version of the classical Müller-Rudin (painting) procedure.

Prof. Dr. Friedrich Simmel, Technical University of Munich, Germany comments:

"The parallel Nanion Orbit 16 setup was crucial for the success of our project, as it allowed us to increase throughput and more quickly screen for optimal conditions for the incorporation of our synthetic DNA channels into lipid bilayer membranes. The small cavity volume of the MECA chips used on the Orbit 16 also helped us to directly prove the translocation of molecules through the channels (from cis to trans side of the membrane), as we could easily demonstrate the accumulation of molecules in the small trans compartment."

Dr. Niels Fertig, CEO of Nanion Technologies, continues:

"We are delighted to see the Orbit 16 displaying its great potential for nanopore research in the exciting development of DNA origami channels. As anticipated, the enabling features of the Orbit such as automation, low noise at high bandwidth and parallel recordings make the technology appealing to the ion channel- and nanopore-communities. We only introduced the Orbit this year and started shipping a few months ago, so it is fantastic to already see user publications in such high ranked journals as Science so early on!"

Dr. Gerhard Baaken, project leader Ionera at the University of Freiburg, enjoins:

"Prof. Simmel's group has been among the earliest alpha-testers of the MECA chip. We were always glad to see how happy they are with its performance and are now extremely gratified by the prominent publication in Science, in which the MECA device and the Ionera-SPREAD automated bilayer formation have played a decisive enabling role in facilitating and speeding up research. Nanion's Orbit 16 is the ideal platform in which to bring the MECA to market, and we are looking forward to our full commercial release in 2013.

The Orbit 16 has been launched earlier in 2012 and the first units are being installed at customer sites. The system will be on display at the Biophysical Society Annual Meeting, in Philadelphia, PA, USA, February 2 – 6, 2013. The Orbit 16 can be used to form and record from solvent-containing lipid bilayers using Ionera's MECA1 or solvent-free bilayers using Nanion's GUV-derived bilayer formation protocols, as already used on the Port-a-Patch.

For the full press release please click here.

1Ionera's MECA technology is commercially available for beta-testing using a dedicated module for the Orbit 16.

2Martin Langecker, Vera Arnaut, Thomas G. Martin, Jonathan List, Stephan Renner, Michael Mayer, Hendrik Dietz, and Friedrich C. Simmel. Synthetic lipid membrane channels formed by designed DNA nanostructures. Science, vol. 338, issue 6109, pp. 932-936. DOI: 10.1126/science.1225624

   

08.11.2012 | Nanion Introduces NPC-Certified Cell Lines

Munich, Germany, November 08, 2012; Nanion’s automated patch clamp platforms are known for their high cell compatibility, even for primary cells and stem cells. Nanion now introduces “Nanion Approved Cells”, where commercially available cell lines from several providers have been evaluated and certified based on cell and platform performance. The approved cells can be directly purchased through Nanion, so that Nanion’s customers get a complete package of APC platform and validated assay.
A large number of cell lines from several providers, including Millipore and CreaCell have been validated on Nanion’s three automated patch clamp platforms, the Port-a-Patch, Patchliner, and the SyncroPatch 96. Parameters such as average seal-resistance, access resistance, cell recording longevity, ion channel expression and success rates for completed recordings were investigated and documented in a standardized way. Success rates for completed recordings were typically above 70%. With Nanion Approved Cells, the user can rest assured that the assay will run optimally, with minimal or no assay development required.

Atsushi Ohtsuki, Customer Support Manager, Nanion Technologies, Japan says:
"The Nanion Approved Cells will be much appreciated by Japanese customers, since the optimization work already has been done by Nanion Technologies, which saves time and reduces the risk of an investment. Additionally, it is also a guarantee, that the customers will encounter minimal problems when starting a new assay on Nanion's automated patch clamp platforms."

Dr. Niels Fertig, CEO of Nanion, continues:
"The certification of commercially available cell lines makes it easier for existing and new customers to invest in new cell lines and our platforms without having to worry about lengthy assay development. It is a well-known fact that Nanion's platforms show great compatibility with a broad range of cells and ion channels, which also is confirmed by the long list of Nanion Approved Cells and scientific publications in high impact journals such as Nature or PNAS. Nanion also certifies cell lines on-demand, meaning that if a customer has a particular cell line of interest, we evaluate and document the cell performance on our platforms, free of charge."

About Nanion Approved Cells
Nanion Approved Cells are commercially available cells, certified on Nanion's three automated patch clamp platforms. Cell and platforms performance as well as ion channel current expression is thoroughly investigated and summarized in a data sheet. The approved cells can be directly purchased from Nanion, so that Nanion's customers get a package of APC platform and validated assay. Nanion also does cell line certification on-demand, if the cell line of interest cannot be found in the list of approved cells. The full list of tested cell lines can be found on Nanion's website.


For the full press release please click here.
   

29.06.2012 | New Patchliner Publication: Toward a New Standard for Early Safety Assessment

Munich, June 29,2012, In a recent publication, scientists at Hoffmann-La Roche, Basel, Switzerland, evaluated the Patchliner for safety testing of drugs affecting the hERG-channel, the cardiac ion channel most commonly associated with drug safety liability issues. In the performed study, the experiments were performed at physiological temperature (35 – 37°C), and the obtained data showed good correlation with pharmacology data recorded using conventional patch clamp.

 Dr. Liudmila Polochuk, the author of the publication titled “Toward a new gold standard for early safety: automated temperature-controlled hERG test on the Patchliner”, concludes:

“…Based on these results, the Patchliner represents an innovative automated electrophysiology platform for conducting the hERG assay that substantially increases throughput and has the advantage of operating at physiological temperature. It allows fast, accurate, and direct assessment of channel function to identify potential proarrhythmic side effects and sets a new standard in ion channel research for drug safety testing.”

 Dr. Polunchuk continues:

“The Patchliner workstation provides stable currents and high- quality giga-Ohm-seal recordings at 37˚C. Based on the validation results, this automated electrophysiology workstation can be used for conducting an advanced hERG assay for new compounds at physiological temperature and may eventually become a new gold standard for ion channel research in safety pharmacology.”

For more information on the performed study, download the full paper here.

 

Patchliner and temperature control

 The Patchliner is a high quality, automated patch clamp platform supporting two modes of temperature control: stable physiological temperatures or rapid application of solutions heated in the pipette. In the latter case, solutions with temperatures up to 65 °C can be added to the patch clamped cells.

For more information about the Patchliner, click here.

For more information about temperature control, click here.

26.02.2012 | Nanion Acquires the SURFE2R Technology for Transporter Protein Analysis

Munich, Germany, February 26, 2012; Nanion acquires the well-established SURFE2R technology, allowing state-of-the-art measurements of transporter protein activity and function. The SURFE2R technology is an excellent enhancement to Nanion’s existing products which until now covered ion channels and nanopores.
Nanion Technologies is one of the leading providers of high quality automated patch clamp systems. Nanion’s efficient and versatile products drastically improve the data output in patch clamp-based ion channel screening, safety testing and scientific research. Since 2003, Nanion has launched three automated patch clamp platforms, the Port-a-Patch (2003), the Patchliner (2006), the SyncroPatch 96 (2010), and recently introduced the Orbit 16 – a device for parallel bilayer recordings. Existing products target ion channels and nanopores in cell- and cell-free membranes for highly detailed information about kinetics, function, and compound pharmacology.

Dr. Niels Fertig, CEO of Nanion Technologies, continues:
“By acquiring the SURFE2R technology developed by IonGate / Scientific Devices Heidelberg, Nanion enters yet another market segment. It is an excellent addition to our product portfolio and a unique platform since it allows direct measurements of transporter activity and function. Further on, the platform has been validated with a wide variety of membrane preparations ranging from bacteria to native cells and cell lines. With this acquisition, Nanion becomes a one-stop-shop for functional membrane protein analysis, extending its product portfolio from screening instrumentation for ion channels and nanopores to now also include transporter proteins. “

 

The SURFE2R product line will be launched during the second half of 2012.

Download the full press release here.

For more information click here.

21.02.2012 | Nanion Introduces the Orbit 16 – a Pioneering Device for Parallel Lipid Bilayer Recordings

Today, Nanion announces the introduction of a completely new product line for efficient analysis of bilayer-reconstituted ion channels and nanopores. The first of these, the Orbit 16, allows for automated formation of, and recordings from 16 bilayers in parallel, combining efficient data generation and ultra-high data quality. The Orbit 16 takes the pain out of bilayer recordings and facilitates efficient data generation through 16 parallel recordings.

Bilayer recording is a well-established technique for in-depth studies of biophysical properties of ion channels and is particularly suited for functional studies on proteins residing in intracellular membranes. Moreover, this technique supports a host of powerful emerging analytical techniques using biological nanopores as molecular sensors.
Despite its proven value, bilayer recording can be very frustrating due to the capricious nature of lipid bilayers which have to be formed manually one by one and which often lack stability. The Orbit 16 speeds up the entire process by the rapid and simultaneous formation of 16, highly stable micrometer-sized bilayers and allows subsequent parallel recordings, thereby enabling efficient data generation. For increased experimental flexibility, two different recording chips are available; either Ionera's microelectrode cavity array (MECA) - or Nanion's-recording chips for work on (proteo-) liposomes, the latter as known from the Port-a-Patch.

Dr. Gerhard Baaken, University of Freiburg, Germany, and founder of Ionera, says:
“Ionera is the developer and will be the provider of the Micro Electrode Cavity Array chip substrates, used with the Orbit 16. We have recently published a study showing that the MECA supports high-resolution polymer sizing with a single biological nanopore (alpha-haemolysin) - one of the most exacting tasks in bilayer recording- in a parallel format. We think that the Orbit 16 will be an ideal environment for our MECA-16 chip and will prove to be a highly enabling technology for bilayer and nanopore research due to the ease of bilayer formation and signal to noise quality of recordings. Thanks to the parallelism of the recordings, the researcher can in most cases obtain data and statistics from one single run.

Dr. Niels Fertig, CEO of Nanion Technologies, continues:
“With the Orbit 16, Nanion enters a new market segment. The Orbit 16 has great potential since it makes bilayer recordings more efficient and accessible to a wider audience. The Orbit 16 offers excellent data quality, i.e. low noise at high bandwidth, in combination with an unmatched data throughput. We anticipate that these features make the Orbit 16 appealing to the ion channel- and nanopore-communities, or anyone who wants to enter the field of bilayer recordings. “

The Orbit 16 has its public premiere at the Biophysical Society Annual Meeting, in San Diego, CA, USA, February 26 – 29, 2012.

Download the full press release here.

15.01.2012 | Nanion celebrates 10th anniversary - still with a strong focus on new innovations


 Nanion - 10 years of automated patch clamp
Munich, Germany, January 15, 2012; Today, Nanion celebrates 10 years of innovation, scientific product development and successful roll-outs of several product families. Nanion is a success story of organic, revenue-based company growth and dedicated young professionals.
10 years ago, Nanion Technologies started out in a small loft at the Institute of Physiology of Ludwig-Maximilian’s University in Munich. Since then, Nanion has grown from 2 to 40 employees and has successfully launched and established four different product families for ion channel drug discovery and research. 

The Port-a-Patch - launched in 2003 - was Nanion’s first product, and is known as the world’s smallest patch clamp rig. It earned great acclaim by making patch clamp accessible to non-experts. The fully automated patch clamp robots, the Patchliner (2006) and SyncroPatch 96 (2010), have been well received within the pharmaceutical industry because of the high data quality, cost-efficiency and experimental flexibility offered. The platforms are also employed for top-notch academic research, resulting in publications in journals such as Nature, Nature Protocol, Science Signalling and PNAS. 


Nanion is a strongly innovation-driven company with several product launches planned for 2012.

Dr. Niels Fertig, co-founder and CEO of Nanion, says:
“Nanion’s strong and sustained growth is based on innovative technology, high performance instrumentation and close customer relations. It has been a really exciting journey gradually turning from start-up into a more mature company with everything that it entails. We are extremely happy about, thankful for and proud of what we have achieved so far and very much look forward to the next decade of product development, science and business growth!”

Michael George, CTO and co-owner of Nanion Technologies continues:
“2012 will be a thrilling year, with several different new products in the pipeline. At Nanion, innovation never ends. This is true as much for brand new ideas and concepts as for existing products. Our customers continue to inspire us to develop hardware and software allowing novel experimental possibilities or just making life easier for the every-day-user. It is very rewarding to get the feedback that we are developing state-of-the-art products enabling completely new strategies for ion channel screening and research.”

Download the full press release here.

Read more:
“Nanion – 10 years of automated patch clamp”

30.11.2011 | Nanion’s SyncroPatch 96 Convinces Big Pharma Automated Patch Clamp Users

Munich, Germany, November 30th, 2011; Nanions ion channel screening platform, the SyncroPatch 96, has been well received within the pharmaceutical industry during the past 12 months. Experienced automated patch clamp users decide in favor of the SyncroPatch 96 because of its high throughput and cost-efficiency in combination with reliable pharmacology for heterologous voltage- and ligand-gated ion channel targets.
The SyncroPatch 96 is Nanion’s high throughput screening platform, capable of generating 9000 data points per day. Since the launch earlier this year, the SyncroPatch 96 platform has been validated with a wide variety of ion channels and cell types, including challenging ligand gated channels such as α7 nicotinic acetylcholine receptors.

Dr. Adam Hendricson, Lead Evaluation, Bristol-Myers Squibb, CT, USA, says:
“The flexibility of the SyncroPatch 96 to run ligand-gated assays without sacrificing throughput or fidelity relative to voltage-gated channels really sets it apart in the gigaseal auto-EP space. When considering different platforms, the SyncroPatch was the only system that met all our critical criteria: >50% giga-seal across multiple cell lines, minimal chip priming and cell-handling, rapid solution exchange for fast agonists, internal solution exchange, ability to multiplex cells in a run, compatibility with external robotic automation, and a highly competitive cost per data point. We run the SyncroPatch on a daily basis and are very happy with its performance and efficiency, and with the excellent, highly responsive applications support offered by Nanion.”

Dr. Henning Draheim, Boehringer-Ingelheim, Germany, continues:
“We carefully researched the market before looking closer at selected APC platforms that may match our internal criteria. We were very impressed by the SyncroPatch 96 system’s flexibility and data quality when testing it on-site, finding that it really performs “as advertised” and definitely fits our needs. In addition, Nanion performed a blind study on the SyncroPatch, testing 22 of our compounds, using a protocol addressing the block of sodium channels in their inactivated state. The obtained compound pharmacology was compared to our manual patch clamp data and the match was fantastic! For me, it was then a straightforward decision for the SyncroPatch 96 and of course it is great when the data speaks for itself when one needs to convince the upper management to purchase state-of-art equipment.”

Niels Fertig, CEO of Nanion Technologies, ads:
“We see a general trend that experienced APC users decide for the SyncroPatch 96. For us, this is a clear indication that the platform delivers what industrial screeners want, in terms of throughput, experimental capabilities and data reliability. Secondly, experienced users challenge the platforms harder – which we welcome, since it proves the capabilities as well as limitations of the tested platforms. As always, we listen carefully to what our customers tell us, to match their hardware and software requirements. At the moment, we’re very busy installing the SyncroPatch 96 worldwide, and we foresee very positive developments in 2012.”

Nanion offers demonstrations of the SyncroPatch 96 at the head quarters in Munich, Germany, and North Brunswick, NJ, USA, or at the customer site.

Download the full press release here

11.11.2011 | Nanion successfully performs automated patch clamp recordings from stem cell-derived neurons

Human iPS cell-derived neurons (iCell neurons) from Cellular Dynamics International were successfully used on Nanion’s 8-channel Patchliner.
To our knowledge, this is the first time stem cell derived neurons have been used on an automated patch clamp device.

Initial experiments showed the presence of voltage-gated Na+, voltage-gated K+ and GABA receptor-mediated currents from these cells. Nanion will continue to work with Cellular Dynamics International to further characterize these cells using the Port-a-Patch, Patchliner and SyncroPatch 96.

Visit Nanion’s booth (#601) at the Society for Neuroscience meeting in Washington D.C. to learn more!  

Download the application note here

24.10.2011 | Nanion opens China office in Beijing

Today, Nanion announces the opening of yet another branch. To meet the needs of the rapidly expanding number of customers in China, the dedicated sales- and support team in Beijing now opens the doors to Nanion Technologies China.
Nanion successfully entered the Chinese market over five years ago, and the installed base of Patchliner and Port-a-Patch instruments has grown constantly ever since. To cover the increasing interest and activities within the fields of ion channel screening, scientific and contract research, the subsidiary Nanion Technologies China is now officially open.

Andy Di, General Manager, Nanion Technologies China, says:
“Nanion’s customer base in China has grown rapidly over the past couple of years. Nanion’s products are very appreciated here because of their vast experimental freedom paired with increased throughput and affordable consumables. Because of their high quality and reliability, products like the SyncroPatch 96, the Patchliner and the Port-a-Patch are attractive for both industrial screening purposes and for dedicated academic research.” 

Niels Fertig, CEO of Nanion Technologies GmbH, continues:
“Because of the growing Chinese market and customer base, it was a natural step to expand in China. With the new subsidiary we are able to cover the ever-increasing demand for product demonstrations and installations as well as to continue giving our Chinese customers premium support. We definitely feel that we have the right people in place for this important step in Nanion’s history, and we look forward to a fruitful collaboration with the Nanion team in China. “

Nanion Technologies China offers live product demonstrations and customer training in Beijing and Shanghai, or at the customer site.

Download the full press release here

16.09.2011 | Nanion’s automated patch clamp platforms show unparalleled results using stem cell derived cardiomyocytes

The Patchliner and the SyncroPatch 96 have successfully been used for compound analysis under current- and voltage clamp recording conditions using different stem cell-derived cardiomyocytes. The exceptional cell-platform-compatibility and the unique experimental possibilities offered by Nanion’s platforms open up whole new avenues for compound safety testing.
Pluripotent stem cell-derived cardiomyocytes have tremendous potentials for cardiac safety and efficacy testing of drug candidates. By offering an authentic cellular environment they are closer to the actual physiological situation compared to cell lines with over-expressed ion channels. All Nanion’s patch clamp platforms, the Port-a-Patch, the Patchliner and the SyncroPatch 96, show exceptional compatibility with stem cell-derived cardiomyocytes provided by Axiogenesis, CDI and Geron/GE Healthcare.

In a joint publication of Nanion and Axiogenesis (Journal of Biomolecular Screening, 2011 July 20), drug-induced modulation of cardiac action potentials using the Port-a-Patch and Patchliner were shown for the first time. Stem cell-derived cardiomyocytes have also been investigated on the SyncroPatch 96, recording from 96 cells in parallel under voltage clamp conditions. Stable whole-cell recordings were obtained with high success rates and expected cardiac currents were recorded (K+, Ca2+, Na+).

Ralf Kettenhofen, Senior Scientist of Axiogenesis, Cologne, Germany, says:
“At Axiogenesis, we were very impressed of the high success rates quickly obtained with Nanion’s platforms.
In our view, the combination of an in vitro cardiac cell model together with higher throughput patch clamp screening technology such as the Patchliner, allows for a cost effective cardiotoxicity prediction in a physiologically relevant cell system.”

Axiogenesis is a provider of pure rodent embryonic stem cell-derived cardiomyocytes (Cor.At®) which have been proven to be a predictive tool in preclinical cardiac safety assessment and drug discovery and development. The Cor.At® cardiomyocytes will now be complemented by human induced pluripotent stell cell-derived (Cor.4U®) cardiomyocytes, which will be launched in Q1 2012.

Niels Fertig, CEO of Nanion Technologies continues:
“Over the past two years, the interest from the pharmaceutical industry in using stem cell-derived cardiomyocytes for safety testing purposes has grown dramatically. To meet this need we have developed our platforms to fit experimental requirements and industry quality standards. It is up to the user to decide: routine analysis in voltage clamp mode, or investigating the compound effect on action potentials since both screening modes are possible. No other APC platform on the market can compete with that at today’s date.”

Download the full press release here. logo_pdf(49 kB)

21.07.2011 | Breakthrough discovery published in PNAS: Dissected, pore-only Nav's measured on the Port-a-Patch

Voltage-gated sodium channels have proven very difficult to crystallize and thus also difficult to obtain a detailed structure of the functional protein. Using a reductionist approach described in the recent PNAS paper, Professor Dan Minor and his research group at the University of San Francisco, USA, together with Nanion scientists, are on their way to reveal the structural impact on selectivity and permeability of sodium channel pores.
In the paper published in PNAS, David Shaya and co-authors show bilayer recordings of functional, pore-only Nav channels. By reducing the complexity of the voltage-gated sodium channels, for example by removing the voltage sensing domain in the extracellular part of the ion channel complex, the researchers hope to be able to crystallize the pore forming domains, as a step towards revealing the full structure of Nav as well as Cav-channels. Indeed, a single-point mutation of the pore-only Nav’s showed altered pore selectivity towards calcium ions.

“It meant a lot of hard work to successfully reconstitute the three functional Nav pore-only channels into lipid bilayers. Luckily, the Port-a-Patch offers fast and straightforward means for ultra-high-quality electrophysiological recordings from ion channels residing in solvent free, artificial bilayers, and enabled me to find the right conditions for the dissected Nav-channels. It was a really cool feeling, to be the first person in the world to record and characterize these ion channels.”
says Dr. Mohamed Kreir, Application Scientist at Nanion, who did the electrophysiology recordings of the dissected sodium ion channel pores.

The method described in this paper, implies a general way to study biophysical aspects of pore structure, and for example the modification by small molecules. The authors suggest that this might be an attractive model for the pharmaceutical industry to reveal compound effects on the pore domain of basically any voltage gated ion channel.

Visit Professor Minor’s web page.
Download the full paper.
For more Nanion-related papers, visit Downloads.
Find more Port-a-Patch information.

06.06.2011 | BMS reports successful screening of advanced ligand gated ion channel targets on SyncroPatch96

Accurate screening of ligand gated channels, high throughput and data quality is now a possible combination thanks to the SyncroPatch 96. 

The SyncroPatch 96 is a full-blown screening platform supporting giga-seal whole-cells recordings from 96 cells in parallel. Allowing full dose response analysis from the individual cells, the SyncroPatch 96 is ideal for studies of both ligand- and voltage-gated ion channels. High quality recordings together with brief and precise compound application grant minimal false-positives and negatives in the drug screening process. 
Find out more by downloading the NEW SyncroPatch 96 product sheet! 

Adam Hendricson, Ph.D., Applied Biotechnology & Lead Evaluation, Bristol-Myers Squibb, Wallingford, CT, USA, says:

“The flexibility of the SyncroPatch 96 to run ligand-gated assays without sacrificing throughput or fidelity relative to voltage-gated channels really sets it apart in the gigaseal auto-EP space.”

Dr. Adam Hendricson’s will be presenting at the following meetings: 

“Changing the Game in Ion Channels – Ultra High-Throughput in Automated Electrophysiology”
World Pharma Congress, Screening Summit: Tools and Technologies for HTS, Philadelphia, PA, USA 

“Bridging the Gaps in Ion Channel Hit-to-Lead with SyncroPatch 96: Ultra-High Throughput Auto-EP”
Aurora Ion Channel Retreat 2011, Vancouver, Canada

 

Ask us for more data, information or a quote by sending an email to This email address is being protected from spambots. You need JavaScript enabled to view it. .

Download the new SyncroPatch 96 Product Sheet here! (780kB)

02.05.2011 | We have moved!

We have grown out of our old facilities and now double the size of our Munich office! With our 1500 m2 we will have plenty of space for:

Expansion of the technical development

Expanded and increased production lines

Running labs for courses, assay development and product demonstrations


In case you are having trouble reaching us during the first week of May, please bear with us! Telephone lines are still being installed, so the most reliable way to get in contact is over This email address is being protected from spambots. You need JavaScript enabled to view it. during this week. We are sorry for the inconvenience!

New address:
Nanion Technologies GmbH
Gabrielenstrasse 9
80636 Munich
Germany

Come and visit us in central Munich and we’ll give you a tour in our Feng Shui compatible facilities!

04.03.2011 | Nanion’s Patchliner exceptionally well received by academic ion channel core facilities

Munich, Germany, March 4th, 2011; The new year has started well for Nanion; in the first weeks of 2011 more than five Patchliners were sold and shipped to academic institutions, intended for advanced ion channel research and screening projects, and are soon to be followed by the first SyncroPatch 96 shipment and installation.

The Patchliner, a highly versatile patch clamp screening platform for increased throughput, has been on the market since 2006. Patchliner customers are evenly distributed over pharmaceutical industry, contract research organizations and academic institutions because of the flexibility and increased throughput of the platform.
Again highlighted by the recent sales, the Patchliner is a much appreciated tool for academic research, mainly because of the high data quality obtained with the platform, and its vast experimental freedom.

Together with three additional Principal Investigators, Dr. Todd Scheuer and Dr. William Catterall invested in both the Patchliner and the Port-a-Patch to form a core facility for ion channel screening and research at the University of Washington, Seattle, USA.
Dr. Todd Scheuer, Research Professor at the Department of Pharmacology, University of Washington, Seattle, says:
“We invested in the Patchliner because of its great experimental flexibility. The diversity of our research projects requires a platform capable of high performance with a multitude of ion channels and cells, as well as experimental possibilities such as action potential- or primary cell recordings.”

In the southern hemisphere, Dr. Steven Petrou, Associate Director at the Florey Neuroscience Institute, and Associate Professor at the Centre for Neuroscience, The University of Melbourne, Australia, invested in multiple Patchliners for the ion channel core facility there.
Dr. Steven Petrou says:
“We recently bought several Patchliners to cover the needs of our neuroscience research projects and to establish an ion channel core facility for the wider ion channel research community. Indeed, the Patchliner has unique experimental features including temperature control, internal perfusion and fast solution exchange. This in combination with supporting giga-Ohm seals and having a throughput corresponding to 100 dose responses per day convinced us that Patchliner will be of great use in our current, but also future research projects.”

Dr. Niels Fertig, CEO of Nanion says:

“We are of course very pleased with this year’s sales trend, which reflects the customers’ appreciation of our high fidelity patch clamp platform and the strong scientific background of our support team. As a consequence, we have expanded the US-office to match the demand for demonstration and to cover possible assay support. Further, the installation of another five Patchliners in top-notch academic laboratories confirms its strength and unparalleled experimental features.”

Download the full press release in English here  logo_pdf(69 kB)

01.02.2011 | Nanion expands the US-office

North Brunswick, NJ, USA, February 1st, 2011; Nanion welcomes Dr. Joerg Oestreich to the team. With Dr. Oestreich’s strong background in electrophysiology screening assays, Nanion continues to offer premium support for the US-market.

Dr. Joerg Oestreich, previously  Study Director at Chantest Corporation, Cleveland, OH, has a solid background in electrophysiology and high throughput drug discovery. Dr. Oestreich received his Ph.D. at the University of Texas at Austin, and continued with post-doc studies at Harvard Medical School, Boston, MA within the field of electrophysiology. Having experience with a multitude of ion channels targets and cellular assays, Dr. Oestreich is a great match for the Nanion team.

Rodolfo Haedo, General Manager of Nanion Inc., says:
“With the rapidly growing number of Patchliner and Port-a-Patch customers, Dr. Oestreich is a needed and welcome contribution to the US-team. I am convinced that his valuable expertise and professional experience will come very handy for covering the ever-increasing demand of product demonstrations, workshops and assay support.”

Joerg Oestreich says:
“I find Nanion’s vision and product portfolio very convincing; the Port-a-Patch and Patchliner are excellent and important research platforms that are not only suited for industrial ion channel research, but also for academia due to their unmatched flexibility and data quality.  They are greatly complemented by the SyncroPatch 96, a screening platform covering the industry’s need for higher throughput and quality in safety testing and drug screening efforts. In addition, Nanion has a very innovative, dynamic, and dedicated team that if required will go through tremendous efforts to  support their customers, and on a personal level is also very pleasant to work with.

Niels Fertig, CEO continues:
“I am happy to welcome Dr. Joerg Oestreich to the team! Despite of the global economic crisis, we see a clearly positive trend in the US sales of our robotic platforms. 2011 will be a very exciting year, especially on the US- and Asian markets with the upcoming installations of the SyncroPatch 96.”

16.12.2010 | Joint publication of the LMU and Nanion in Science Signaling

Munich, Germany, December 16th, 2010; Researches from the LMU and Nanion Developed a Planar Patch Clamp Approach to Characterize Ionic Currents from Intact Lysosomes

Since its launch in the early 1980s, the patch clamp method has been extensively used to study ion channels in the plasma membrane, but its application to the study of intracellular ion channels has been limited. Unlike the plasma membrane, intracellular membranes are usually not stable enough to withstand mechanical manipulation by glass electrodes during seal formation and rupturing of the membrane. To circumvent these problems, we developed a method involving the immobilization of isolated organelles on a solid matrix planar glass chip. This glass chip contains a microstructured hole that supports the formation of gigaseals and subsequent electrophysiological recordings despite the high fragility of intracellular membranes.

In a collaboration between the Teams of Prof. Christian Wahl-Schott and Prof Martin Biel from the LMU and Dr. Andrea Brüggemann from Nanion Technologies it was possible to develop a method, which allows to record the ionic currents from intact Lysosomes. The detailed Method is published in Science Signaling, 7 December 2010.

We want to continue with this successful collaboration and further develop this method for other organelles, says Andrea Brüggemann.


For more information please see the press release of the LMU and the press release of the CeNS.

19.04.2010 | Final success in Nanion’s opposition against Molecular Devices patent

'Increased freedom to operate for everyone in automated patch clamping'

Munich, Germany, April 15th, 2010; Nanion Technologies GmbH (Nanion), a supplier of automated, parallel patch-clamp systems based in Munich, Germany, today announced that a Board of Appeal of the European Patent Office (EPO) has overturned an earlier decision of the Opposition Division to uphold patent EP 1,040,349 owned by Molecular Devices, Inc. (MDC).

Download the complete press release here in English logo_pdf (105kb)

15.02.2010 | Product Catalog has been updated

Nanion's Product Catalog has been updated. Check it out for the latest product information.

SyncroPatch®96 - Giga-seal recordings from 96 cells in parallel

Suction Control Pro - Pressure clamp extension for Nanion's second generation Suction Control for the Port-a-Patch®

Ultra-Fast Perfusion System - Nanion's new Add-On for the Port-a-Patch®


Download our new Product Catalog here logo_pdf(13.789kb)

26.11.2009 | Nanion Overall Winner of the Step Award 2009

Munich, Germany, Nov. 26th, 2009. Nanion Technologies GmbH was announced the overall winner of the STEP Award 2009, a business award for innovative and fast-growing companies. More than 120 companies competed in this year's STEP Award and Nanion as the grand prize-winner receives a cash prize of € 50,000 and a comprehensive service package worth the same amount.

http://www.step-award.de

Download the complete press release in English logo_pdf (40kb)

21.07.2009 | New Patchliner Application Note: Heat activation of TRPV1

Nanion’s Patchliner® allows temperature controlled experiments, either at physiological temperatures or by application of temperature jumps.


Here, TRPV1 receptors were activated by noxious temperatures (>42 ˚C) using the temperature regulation feature of the Patchliner®. Solution were heated to temperatures up to 60 ˚C in the pipette and rapidly applied to the cell, transiently activating TRPV1 channels. The temperature responses were compared to capsaicin activation, and could also be blocked by co-application of antagonist and tempered solutions.

02.07.2009 | Nanion is winner of the 'Deutscher Gründerpreis 2009'

During the award ceremony in Berlin, Nanion was announced winner of the Deutscher Gründerpreis 2009. The Deutscher Gründerpreis is the most prestigious award for outstanding entrepreneurs in Germany.

The prize includes coaching by Porsche Consulting and mentorship for Nanion. The mentor for Nanion is Dr. Jürgen Heraeus, Chairman of the Supervisory Board of Heraeus Holding.

Download the complete press release here in English logo_pdf (127kb), in German logo_pdf(125kb)

23.06.2009 | Nanion and Axiogenesis present recordings

Nanion and Axiogenesis present parallel patch clamp recordings of action potentials from Cor.At® Cardiomyocytes Stem cell derived cardiomyocytes were analyzed using Nanion’s Patchliner® and Port-a-patch® to validate the ion channel composition, the presence of action potentials and the effects of compounds on cardiac channels.


Download the complete press release here in English(49kb), in German (55kb)

Download the Patchliner application note here  (624kb)

Download the Port-a-Patch application note here  (557kb)

Axiogenesis website: www.axiogenesis.com

03.06.2009 | Nanion nominated for 'Deutscher Gründerpreis'

Nanion is once again nominated for a prestigious award: the German Founder Award (Deutscher Gründerpreis).

For more information about the award (in German):

http://www.deutscher-gruenderpreis.de/owx_medien/media17/1736.pdf

For more information about Nanion’s nomination (in German):
http://www.deutscher-gruenderpreis.de/owx_medien/media17/1734.pdf

Deutscher  Gründerpreis 2009


15.04.2009 | Nanion's SyncroPatch®96 validated with various targets and cells

The SyncroPatch®96, a high quality, high throughput patch clamp ion channel screening platform, shows impressive results with a wide variety of ion channel targets and cell lines.

Download the complete press release here logo_pdf(47kb)

17.02.2009 | Nanion opens US-office in New Jersey

Nanion today announces the opening of Nanion Technologies Inc. with headquarters in North Brunswick, NJ, USA. To support the increasing demand of Nanion’s products, and to continue giving premium customer service, Nanion now expands its presence in the American market.

Download the complete press release here  logo_pdf (46kb)

Press release in German logo_pdf (48kb)